<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Epidermal growth factor receptor blockers for the treatment of ovarian cancer - Morrison, J - 2018 | Cochrane Library</title> <meta content="Epidermal growth factor receptor blockers for the treatment of ovarian cancer - Morrison, J - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007927.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Epidermal growth factor receptor blockers for the treatment of ovarian cancer - Morrison, J - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007927.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007927.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Epidermal growth factor receptor blockers for the treatment of ovarian cancer" name="citation_title"/> <meta content="Jo Morrison" name="citation_author"/> <meta content="Musgrove Park Hospital" name="citation_author_institution"/> <meta content="jo_morrison@doctors.org.uk" name="citation_author_email"/> <meta content="Clemens Thoma" name="citation_author"/> <meta content="Springer Nature" name="citation_author_institution"/> <meta content="Richard J Goodall" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Thomas J Lyons" name="citation_author"/> <meta content="University of Bristol" name="citation_author_institution"/> <meta content="Kezia Gaitskell" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Alison J Wiggans" name="citation_author"/> <meta content="Musgrove Park Hospital" name="citation_author_institution"/> <meta content="Andrew Bryant" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD007927.pub4" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/10/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007927.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007927.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007927.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal [adverse effects, *therapeutic use]; Antibodies, Monoclonal, Humanized [adverse effects, therapeutic use]; Antineoplastic Agents [adverse effects, *therapeutic use]; Deoxycytidine [*analogs &amp; derivatives, therapeutic use]; ErbB Receptors [*antagonists &amp; inhibitors]; Erlotinib Hydrochloride [adverse effects, therapeutic use]; Neoplasm Recurrence, Local [drug therapy]; Ovarian Neoplasms [*drug therapy, mortality]; Piperidines [adverse effects, therapeutic use]; Progression‐Free Survival; Quality of Life; Quinazolines [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007927.pub4&amp;doi=10.1002/14651858.CD007927.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WcPhDegp";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007927\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007927\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ja","ko","ms","fa","th"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007927.pub4",title:"Epidermal growth factor receptor blockers for the treatment of ovarian cancer",firstPublishedDate:"Oct 15, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007927.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007927.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007927.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007927.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007927.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007927.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007927.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007927.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007927.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007927.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2297 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007927.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-sec-0122"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-sec-0045"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-sec-0046"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-sec-0071"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-sec-0111"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/appendices#CD007927-sec-0127"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/table_n/CD007927StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/table_n/CD007927StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Epidermal growth factor receptor blockers for the treatment of ovarian cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information#CD007927-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jo Morrison</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information#CD007927-cr-0003">Clemens Thoma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information#CD007927-cr-0004">Richard J Goodall</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information#CD007927-cr-0005">Thomas J Lyons</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information#CD007927-cr-0006">Kezia Gaitskell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information#CD007927-cr-0007">Alison J Wiggans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information#CD007927-cr-0008">Andrew Bryant</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information/en#CD007927-sec-0134">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 October 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007927.pub4">https://doi.org/10.1002/14651858.CD007927.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007927-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007927-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007927-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007927-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007927-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD007927-abs-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007927-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007927-abs-0001" lang="en"> <section id="CD007927-sec-0001"> <h3 class="title" id="CD007927-sec-0001">Background</h3> <p>This is an update of a previously published version of the review (Issue 10, 2011).</p> <p>Epithelial ovarian cancer (EOC) is the seventh most common cause of cancer death among women worldwide. Treatment consists of a combination of surgical debulking and platinum‐based chemotherapy. Between 55% and 75% of women who respond to first‐line therapy experience relapse within two years. Second‐line chemotherapy is palliative and aims to reduce symptoms and prolong survival. Improved understanding about the molecular basis of EOC has led to the development of novel agents, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and anti‐EGFR antibodies. </p> </section> <section id="CD007927-sec-0002"> <h3 class="title" id="CD007927-sec-0002">Objectives</h3> <p>To compare the effectiveness and harmful effects of interventions that target the epidermal growth factor receptor in the treatment of epithelial ovarian cancer (EOC). </p> </section> <section id="CD007927-sec-0003"> <h3 class="title" id="CD007927-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecological Cancer Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL; 2010, Issue 4), MEDLINE, and Embase up to October 2010. We also searched registers of clinical trials, abstracts of scientific meetings, and reference lists of included studies, and we contacted experts in the field. This update includes further searches up to September 2017. </p> </section> <section id="CD007927-sec-0004"> <h3 class="title" id="CD007927-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing anti‐EGFR agents with or without conventional chemotherapy versus conventional chemotherapy alone or no treatment in women with histologically proven EOC. </p> </section> <section id="CD007927-sec-0005"> <h3 class="title" id="CD007927-sec-0005">Data collection and analysis</h3> <p>Two review authors independently abstracted data, assessed risk of bias, and performed GRADE assessment. </p> </section> <section id="CD007927-sec-0006"> <h3 class="title" id="CD007927-sec-0006">Main results</h3> <p>From 6105 references obtained through the literature search and an additional 15 references derived from grey literature searches, we identified seven RCTs that met our inclusion criteria and included 1725 participants. Trial results show that after first‐line chemotherapy is provided, maintenance treatment with erlotinib (EGFR tyrosine kinase inhibitor (TKI)) probably makes little or no difference in overall survival (hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.81 to 1.20; one study; 835 participants; low‐certainty evidence) and may make little or no difference in progression‐free survival (HR 1.05, 95% CI 0.90 to 1.23; one study; 835 participants; very low‐certainty evidence). Less than 50% of participants provided quality of life data, and study authors reported these results incompletely. The certainty of evidence is very low, but treatment may reduce quality of life compared to observation. </p> <p>Treatment with an EGFR TKI (vandetanib) for women with relapsed EOC may make little or no difference in overall survival (HR 1.25, 95% CI 0.80 to 1.95; one study; 129 participants; low‐certainty evidence) and may make little or no difference in progression‐free survival (HR 0.99, 95% CI 0.69 to 1.42; one study; 129 participants; very low‐certainty evidence). In treating patients with relapse, giving EGFR TKI may slightly increase some toxicities, such as severe rash (risk ratio (RR) 13.63, 95% CI 0.78 to 236.87; one study; 125 participants; very low‐certainty evidence). Quality of life data were not available for meta‐analysis. </p> <p>Anti‐EGFR antibody treatment in relapsed EOC may or may not make a difference to overall survival (HR 0.93, 95% CI 0.74 to 1.18; four studies; 658 participants; moderate‐certainty evidence) and may or may not have any effect on progression‐free survival (HR 0.90, 95% CI 0.70 to 1.16; four studies; 658 participants; low‐certainty evidence). Anti‐EGFR antibody treatment may or may not increase side effects, including severe nausea and/or vomiting (RR 1.27, 95% CI 0.56 to 2.89; three studies; 503 participants; low‐certainty evidence), severe fatigue (RR 1.06, 95% CI 0.66 to 1.73; I² = 0%; four studies; 652 participants; low‐certainty evidence), and hypokalaemia (RR 2.01, 95% CI 0.80 to 5.06; I² = 0%; three studies; 522 participants; low‐certainty evidence). Severe diarrhoea rates were heterogeneous across studies (RR 2.87, 95% CI 0.59 to 13.89; four studies; 652 participants; low‐certainty evidence), and subgroup analysis revealed that severe diarrhoea was more likely with pertuzumab (RR 6.37, 95% CI 1.89 to 21.45; I² = 0%; three studies; 432 participants; low‐certainty evidence) than with seribantumab treatment (RR 0.38, 95% CI 0.07 to 2.23; I² = 0%; one study; 220 participants; very low‐certainty evidence). Quality of life data were incompletely reported, and we were unable to combine them in a meta‐analysis. </p> </section> <section id="CD007927-sec-0007"> <h3 class="title" id="CD007927-sec-0007">Authors' conclusions</h3> <p>Current evidence suggests that an anti‐EGFR single‐agent biological treatment (EGFR TKI or anti‐EGFR antibody) makes little or no difference to survival, either as maintenance treatment after first‐line chemotherapy or in association with chemotherapy in recurrent cancer. Anti‐EGFR therapy may increase some side effects and may or may not reduce quality of life. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007927-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007927-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007927-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007927-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007927-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007927-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007927-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD007927-abs-0014">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007927-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007927-abs-0004" lang="en"> <h3>Do epidermal growth factor receptor (EGFR) inhibitors, alone or with chemotherapy, improve outcomes for women with epithelial ovarian cancer (EOC)? </h3> <p><b>What is the aim of this review?</b> <br/> The aim of this review was to find out if medicines that inhibit epidermal growth factor receptors improve the outcomes of women with EOC and to identify the harms of treatment. We sought to collect and analyse results of all relevant studies to answer this question and found seven studies. </p> <p><b>What are the key messages of the review?</b> <br/> Limited evidence suggests that there is little or no benefit from taking anti‐EGFR agents either alongside chemotherapy at relapse, or as maintenance treatment after first‐line chemotherapy for EOC, and that some side effects may be increased. </p> <p><b>What was studied in the review?</b> <br/> Approximately a quarter of gynaecological cancers are of ovarian origin, although they account for half of all deaths related to gynaecological cancers. The annual incidence worldwide is about 6.6 cases per 100,000 women, with an annual mortality rate of four deaths per 100,000 women, as three‐quarters of these cases are diagnosed at an advanced stage. Treatment usually consists of a combination of surgery to remove as much of the visible cancer as possible (debulking surgery) and platinum‐based chemotherapy. Most cases of EOC (70% to 80%) respond to chemotherapy. Unfortunately, most women with advanced disease experience relapse and ultimately die because of resistance to chemotherapy. </p> <p>EGFR is involved in controlling cell growth. High EGFR activity is linked to development of EOC and to poor outcomes. Preventing EGFR activity is an attractive target for novel therapeutic agents. Anti‐EGFR agents have been developed and have been tried in combination with chemotherapy or as maintenance treatment after chemotherapy. </p> <p><b>What are the main results of the review?</b> <br/> This review found evidence from seven studies on the effects of an anti‐EGFR antibody or an EGFR tyrosine kinase inhibitor (TKI) (erlotinib and vandetanib) in women treated for EOC. This was given either as maintenance treatment, following completion of first‐line chemotherapy, or for EOC that had grown after initial treatment (recurrent or refractory disease) . </p> <p>We found low‐certainty evidence to suggest that following first‐line chemotherapy, maintenance treatment with erlotinib probably makes little or no difference in overall survival, and very low‐certainty evidence that it makes little or no difference in progression‐free survival (time before cancer starts to grow again). Treatment may reduce quality of life compared to no treatment (observation), but minimal data were available, and we have very low‐certainty about these findings. Data on adverse events were not available for inclusion in the meta‐analysis. </p> <p>We found low‐certainty evidence to suggest that treatment with vandetanib for women with relapsed EOC probably makes little or no difference in overall survival, and very low‐certainty evidence that it makes little or no difference in progression‐free survival. Vandetanib treatment probably increases the risk of a severe rash, but data on other side effects were of very low‐certainty due to small numbers and very wide confidence intervals. </p> <p>We found moderate‐certainty evidence to show that treatment with an anti‐EGFR antibody probably makes little or no difference in overall survival, and low‐certainty evidence suggesting that it may make little or no difference in progression‐free survival in cases of relapsed disease. Treatment with the anti‐EGFR antibody pertuzumab probably increases the risk of diarrhoea (low‐certainty), but evidence for its effect on other side effects is of very low‐certainty due to low numbers of events. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007927-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007927-sec-0122">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007927-sec-0192">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007927-sec-0122"></div> <h3 class="title" id="CD007927-sec-0123">Implications for practice</h3> <section id="CD007927-sec-0123"> <p>Data demonstrate little or no difference between treatment and observation/control arms. These data suggest that alone, inhibition of the epidermal growth factor receptor (EGFR) pathway has minimal, if any, beneficial effect and may cause harm due to side effects that erode quality of life. </p> </section> <h3 class="title" id="CD007927-sec-0124">Implications for research</h3> <section id="CD007927-sec-0124"> <p>Although the concept of targeted therapy and a 'magic bullet' in cancer treatment is highly attractive, control of cell growth is, from an evolutionary point of view, key to cell survival. Cells have evolved a highly complex and interconnected set of pathways and cross‐talk with their environment, which have a high level of redundancy, to maintain cell survival. Targeting a single point of failure within a cancer cell, which has high genetic instability due to tumour suppressor gene function loss, presents a greater challenge once the cell is placed within a complex tumour microenvironment rather than in a petri dish. However, EGFR tyrosine kinase inhibitors (TKIs) have been shown in recent clinical trials to be effective for some lung cancers (<a href="./references#CD007927-bbs2-0082" title="OkamotoI , MoritaS , TashiroN , ImamuraF , InoueA , SetoT , et al. Real world treatment and outcomes in EGFR mutation‐positive non‐small cell lung cancer: long‐term follow‐up of a large patient cohort. Lung Cancer2018;117:14‐9. [DOI: 10.1016/j.lungcan.2018.01.005] ">Okamoto 2018</a>). </p> <p>Biological therapies, similar to conventional chemotherapy, may be more effective when given in combination to attack complex pathways at several points simultaneously. This is likely to also produce greater toxicity, as normal cells are less likely to be protected due to reduced specificity. Candidates for the combination approach include agents that inhibit mammalian target of rapamycin (mTOR) and phosphatidylinositol 3‐kinase (PI3K)‐Akt pathways (<a href="./references#CD007927-bbs2-0066" title="GlaysherS , BoltonLM , JohnsonP , AtkeyN , DysonM , TorranceC , et al. Targeting EGFR and PI3K pathways in ovarian cancer. British Journal of Cancer2013;109:1786‐94. [DOI: 10.1038/bjc.2013.529] ">Glaysher 2013</a>). </p> <p>In addition, subtleties in cell‐cell communication and interaction with tissue stroma, the medium in which cancer cells exist, are not well reproduced in conventional monocultures in vitro. More complex models of the tumour environment, including non‐cancerous cells (e.g. connective tissue components such as collagen, cells of the immune system, and cells from small blood vessels), may be needed for the complexity of the cancer cell environment to be fully understood. </p> <p>'Individualised therapy' ‐ the challenge and opportunity for modern oncology treatment ‐ remains a holy grail outside of a few specific tumour types. Tailoring treatment to specific cancer mutations will require a radical change in large phase III study design. It would be useful if studies of different agents, with different tumour biology targets, could be conducted in parallel, so that eligible women could be allocated to appropriate trial comparison arms depending on their individual tumour biology. This will require the co‐operation of researchers and pharmaceutical companies and will present a challenge to regulatory authorities, but this approach would more rapidly generate meaningful data for women than would conventionally designed studies. </p> <p>Presenting data on median survival along with standard deviations would be useful for subsequent meta‐analyses. This would also aid decision‐making because HR data presented within a summary of findings table are more difficult to interpret and weigh than is the time benefit offered by treatment. This is the information women often seek, and presenting these items as a visual 'decision aid' would prove valuable to consumers. </p> <p>Of primary importance, no treatment for advanced epithelial ovarian cancer (EOC), which is of palliative intent from the outset for the majority, should be provided, nor its results interpreted, without full disclosure of toxicity and quality of life analyses. The benefit of a modest improvement in progression‐free overall survival needs to be balanced carefully against any increase in unpleasant and debilitating side effects. This balance is likely to be different for each woman, but the information should be made available so women can make informed decisions about their care. This approach would lead us towards true 'individualised medicine' based on patient decisions made with full knowledge of harms and benefits, with consideration of patient preferences, values, and goals ‐ not just targeting treatment to tumour biology. In addition, for expensive treatments, which may provide only modest effects in select groups, cost‐benefit analyses would be important to aid decision‐makers as they assess the value of new treatments to a population/society. </p> <p>Further updates of this review are not planned because it is unlikely that additional studies that meet the review inclusion criteria will be performed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007927-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007927-sec-0036"></div> <div class="table" id="CD007927-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy<br/> <b>Setting:</b> hospital outpatient treatment of women with ovarian/fallopian tube/primary peritoneal cancer after response to first‐line chemotherapy<br/> <b>Intervention:</b> EGFR tyrosine kinase inhibitor (TKI)<br/> <b>Comparison:</b> observation alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with observation alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with EGFR tyrosine kinase inhibitor (TKI)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median 50.8 months in the EGFR TKI group vs 59.1 months in the observation arm</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.99<br/> (0.81 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>835<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome unlikely to be affected by blinding. due to the way HRs are calculated, the assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median PFS of 12.7 months in the EGFR TKI group vs 12.4 months in the observation arm </p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.05<br/> (0.90 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>835<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>due to the way HRs are calculated, the assumed and corresponding risks were not estimated.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with EORTC QLQ‐C30 and OV28 (Ovarian Cancer Module) questionnaires </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>"Global health/QOL scores showed a significant overall difference between the two treatment arms during the first year (P 0.0102) in favour of the observation arm. In addition, the QLQ‐C30 found statistically significant differences at the 5% level in symptom levels for diarrhoea, loss of appetite, nausea/vomiting, and fatigue, with worse symptom scores for the erlotinib arm. None of the scales, however,reported differences of 10 points except for the diarrhoea [sic] scale in which differences of more than 20 points were observed at most assessments during the first year. Sensitivity analyses by means of imputation revealed similar results". </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>835<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysable data were not provided in the published paper or after communication with the study author, and so we were unable to analyse or exclude selective reporting bias. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; EGFR: epidermal growth factor receptor; HR: hazard ratio; RR: risk ratio; OR: odds ratio; PFS: progression‐free survival; QOL: quality of life; QLQ‐C30: Quality of Life Questionnaire C30; RCT: randomised controlled trial; TKI: tyrosine kinase inhibitor. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><a href="./references#CD007927-bbs2-0069" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐4. ">GRADE Working Group</a> grades of evidence<br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels for imprecision (confidence intervals that cross zero and single study) and inability to assess inconsistency, as results were based on a single study.<br/> <sup>b</sup>Downgraded by three levels due to risk of bias (unblinded study); imprecision (confidence intervals that cross zero and single study); and inability to assess inconsistency, as results were based on a single study.<br/> <sup>c</sup>Downgraded by three levels due to the possibility of selective reporting bias (incompletely reported predefined outcome, so possibility of selective outcome reporting); imprecision; and risk of bias (unblinded), as no data were available to analyse effect and outcome was highly likely to be affected by lack of blinding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007927-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> treatment of relapsed epithelial ovarian cancer<br/> <b>Setting:</b> hospital outpatient treatment of women with relapsed ovarian/fallopian tube/primary peritoneal cancer<br/> <b>Intervention:</b> EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy<br/> <b>Comparison:</b> chemotherapy alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with chemotherapy alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median OS for chemotherapy alone was 18 months compared to 14 months in the chemotherapy plus EGFR TKI arm. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.25<br/> (0.80 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome unlikely to be affected by blinding. due to the way HRs are calculated, the assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median PFS for chemotherapy only was 3.5 months compared to a median PFS of 3.0 months in the chemotherapy plus EGFR TKI arm. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.99<br/> (0.69 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>due to the way HRs are calculated, the assumed and corresponding risks were not estimated.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 rash<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or CommonTerminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 13.63<br/> (0.78 to 236.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100<br/> (1 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 nausea ± vomiting<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/> (0.16 to 2.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<br/> (1 to 20) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 fatigue<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.28 to 2.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 100<br/> (3 to 26) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: cardiac toxicity (any grade)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.24<br/> (0.26 to 107.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/> (4 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life: not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No QoL data included in the publication</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; CTCAE: Common Terminology Criteria for Adverse Events; EGFR: epidermal growth factor receptor; HR: hazard ratio; PFS: progression‐free survival; QoL: quality of life; RCT: randomised controlled trial; RR: risk ratio; TKI: tyrosine kinase inhibitor </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><a href="./references#CD007927-bbs2-0069" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐4. ">GRADE Working Group</a> grades of evidence<br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Outcome unlikely to be affected by lack of blinding.<br/> <sup>b</sup>Downgraded by two levels due to imprecision (one small study, wide confidence intervals that cross zero, and too few events for adequate power).<br/> <sup>c</sup>Downgraded by three levels due to risk of bias (blinding absent or unclear); imprecision; and inability to assess inconsistency (one small study, wide confidence intervals that cross zero, and too few events for adequate power). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007927-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> treatment of relapsed epithelial ovarian cancer<br/> <b>Setting:</b> hospital outpatient treatment of women with ovarian/fallopian tube/primary peritoneal cancer after response to first‐line chemotherapy<br/> <b>Intervention:</b> anti‐EGFR antibody plus chemotherapy<br/> <b>Comparison:</b> chemotherapy alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative<br/> effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with chemotherapy alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐EGFR antibody plus chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median OS by study in intervention and placebo groups, respectively</p> <p><a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>: "overall survival are not yet evaluable" </p> <p><a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>: 28.2 months vs median overall survival not reached </p> <p><a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>: median OS 10.2 months vs 8.4 months </p> <p><a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>: median OS 13.7 months vs 10.12 months </p> <p><a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>: median OS 13 months and 13.1 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.93<br/> (0.74 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>658<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome unlikely to be affected by blinding. due to the way HRs are calculated, the assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median progression‐free survival (PFS) by study in intervention and placebo groups, respectively </p> <p><a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>: median PFS 9.5 months vs 10.7 months </p> <p><a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>: median PFS 34.1 weeks vs 40.0 weeks </p> <p><a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>: median PFS 4.3 months vs 2.6 months </p> <p><a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>: median PFS 3.75 months vs 3.68 months </p> <p><a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>: median PFS 2.9 months and 2.6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.90<br/> (0.70 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>658<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>due to the way HRs are calculated, the assumed and corresponding risks were not estimated.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 to 4 anaemia<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.47 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>652<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/> (37 to 116) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 diarrhoea<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.87<br/> (0.59 to 13.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>652<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diarrhoea differential side effect dependent upon type of anti‐EGFR antibody</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/> (12 to 283) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 diarrhoea ‐ pertuzumab<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.37<br/> (1.89 to 21.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>432<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diarrhoea was a more consistent side effect with pertuzumab when separated from trials of other anti‐EGFR inhibitors </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000<br/> (26 to 299) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 diarrhoea ‐ seribantumab<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.38<br/> (0.07 to 2.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/> (3 to 84) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 nausea ± vomiting<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/> (0.56 to 2.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>503<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/> (23 to 118) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 fatigue<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/> (0.66 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>652<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (63 to 164) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 hypokalaemia<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.01<br/> (0.80 to 5.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>522<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/> (21 to 132) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Quality of life (QoL) (Hilpert data 2016 ‐ see additional references for <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a> study): abdominal/gastrointestinal QoL (QLQ‐OV28) score 3.9 (95% CI ‐3.3 to 11.2); diarrhoeal symptoms QoL score worse on pertuzumab; score difference 21.2 (95% CI 10.1 to 32.3; P = 0.0003). <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a> (reported only in conference abstract form ‐ see Lalla 2008 in subsidiary references for <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>): "The median time to symptom deterioration was 1.7 months in the gemcitabine+placebo arm vs. 3.8 months in the gemcitabine+pertuzumab arm (HR = 0.62, 95% CI: 0.36‐1.05). Symptom improvement (≥ 3 point increase in FOSI) occurred in 28 women (43%) given gemcitabine+pertuzumab, compared to 18 (28%) in those receiving gemcitabine+placebo". </p> <p>ClinicalTrials.gov identifier: NCT00096993</p> <p>This outcome was included in the original version of this review; no new results have been identified. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life was not reported consistently; narrative description of data is provided in review text, as data could not be added to meta‐analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; CTCAE: Common Terminology Criteria for Adverse Events; EGFR: epidermal growth factor receptor; HR: hazard ratio; OS: overall survival; PFS: progression‐free survival; QLQ‐OV28: European Organization for Research and Treatment of Cancer module for ovarian cancer; QoL: quality of life; RCT: randomised controlled trial; RR: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><a href="./references#CD007927-bbs2-0069" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐4. ">GRADE Working Group</a> grades of evidence<br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Outcome unlikely to be affected by lack of blinding. Downgraded by one level due to imprecision (wide confidence intervals that cross zero).<br/> <sup>b</sup>Downgraded by two levels due to lack of blinding in studies or unclear method of randomisation in studies and imprecision.<br/> <sup>c</sup>Downgraded by three levels for inconsistency between studies of different anti‐EGFR antibodies; imprecision; and lack of blinding or unclear method of randomisation in studies.<br/> <sup>d</sup>Downgraded by three levels due to imprecision (wide confidence intervals that cross zero and too few events for adequate power); lack of blinding or unclear method of randomisation in studies; and inconsistency (one study).<br/> <sup>e</sup>Downgraded by 3+ levels due to risk of bias (lack of blinding); inability to gauge inconsistency (only one study); minimal data presented and inability to assess adequately but wide confidence intervals; selective reporting bias as data collected but not presented in final publication; and risk of indirectness as symptom may be due to progression of disease rather than to treatment. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007927-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007927-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007927-sec-0147">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD007927-sec-0037"></div> <section id="CD007927-sec-0038"> <h3 class="title" id="CD007927-sec-0038">Description of the condition</h3> <p>In 2012, 238,719 women worldwide received the diagnosis of epithelial ovarian cancer (EOC), and 151,917 died, corresponding to an annual age‐standardised incidence of 6.1 cases per 100,000 women, an annual mortality rate of 3.8 deaths per 100,000, and a cumulative lifetime risk of 0.5% (<a href="./references#CD007927-bbs2-0067" title="FerlayJ , SoerjomataramI , ErvikM , DikshitR , EserS , MathersC , et al. GLOBOCAN 2012v1.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase. Lyon: IARCPress, 2013, issue No. 11 [Internet]. ">GLOBOCAN 2012</a>). In terms of age‐standardised incidence and mortality, EOC is the seventh most common cancer among women. Onset of the disease is often insidious; symptoms are vague and may mimic other conditions. This may lead to a delay in diagnosis, and three‐quarters of women with EOC receive the diagnosis when the disease has spread throughout the abdomen (stage III or IV) (<a href="./references#CD007927-bbs2-0086" title="ShepherdJH . Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology1989;96(8):889‐92. ">Shepherd 1989</a>). By this time, five‐year survival is 20% to 30% (<a href="./references#CD007927-bbs2-0073" title="JemalA , SiegelR , WardE , HaoY , XuJ , MurrayT , et al. Cancer statistics. Cancer Journal for Clinicians2008;58(2):71‐96. ">Jemal 2008</a>). Epithelial ovarian cancer (EOC), which may arise from the surface of the ovary, accounts for 90% of all ovarian cancers and typically presents in postmenopausal women, with a peak incidence when women are in their early sixties, although it does occur in younger women and is often associated with genetic predispositions (<a href="./references#CD007927-bbs2-0084" title="QuinnM , BabbB , BrockA , JonesJ . In: Office for National Statistics, editor(s). Cancer Trends in England and Wales. London: The Stationery Office, 2001. ">Quinn 2001</a>). More recent data suggest that the site of origin of the most common type of EOC (high grade serous adenocarcinoma) could be the epithelial lining of the fallopian tubes. Intraepithelial precursor lesions (serous tubal intraepithelial carcinoma or serous tubal in situ carcinoma (STIC) lesions) are commonly found at the fimbrial ends of fallopian tubes removed from women at high risk of developing EOC due to <i>BRCA</i> mutations (<a href="./references#CD007927-bbs2-0064" title="EricksonBK , ConnerMC , LandenCN . The role of the fallopian tube in the origin of ovarian cancer. American Journal of Obstetrics and Gynecology2013;209(5):409‐14. ">Erickson 2013</a>). </p> </section> <section id="CD007927-sec-0039"> <h3 class="title" id="CD007927-sec-0039">Description of the intervention</h3> <p>Management of advanced EOC consists of debulking surgery and platinum‐based chemotherapy, with or without the addition of a taxane (<a href="./references#CD007927-bbs2-0076" title="MorrisonJ , HaldarK , KehoeS , LawrieTA . Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD005343] ">Morrison 2012</a>; <a href="./references#CD007927-bbs2-0088" title="StewartL , Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer. Cochrane Database of Systematic Reviews1999, Issue 1. [DOI: 10.1002/14651858.CD001418] ">Stewart 1999</a>). Randomised controlled trials (RCTs) found that, in advanced disease not thought amenable to primary debulking surgery, there was no difference in survival if surgery was performed before or after the first three cycles of chemotherapy (<a href="./references#CD007927-bbs2-0090" title="VergoteI , TropéCG , AmantF , KristensenGB , SardiJE , EhlenT , et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine2010;363(10):943‐53. ">Vergote 2010</a>; <a href="./references#CD007927-bbs2-0075" title="KehoeS , HookJ , NankivellM , JaysonGC , KitchenerH , LopesT , et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open‐label, randomised, controlled, non‐inferiority trial. The Lancet2015;386(9990):249‐57. ">Kehoe 2015</a>). Despite good initial response to platinum agents and taxanes, most women will experience relapse, will require further treatment with chemotherapy, and eventually will develop resistance to conventional chemotherapeutic agents. </p> <p>Conventional chemotherapeutic agents have shown activity on all rapidly dividing cells, hence the common side effects such as bone marrow suppression and mucositis. Increasing knowledge of the genetic basis for cancer has led to the development of novel reagents that target cancer‐specific pathways. It is hoped that these reagents will spare normal cells and will reduce the toxic side effects of chemotherapy, in addition to conferring an enhanced therapeutic effect. </p> </section> <section id="CD007927-sec-0040"> <h3 class="title" id="CD007927-sec-0040">How the intervention might work</h3> <p>Cancer cells, just like normal cells, can respond to external stimulation via growth factor receptors. These pathways are often mutated in cancer and therefore serve as a potential target for control of cancer cell growth. </p> <section id="CD007927-sec-0041"> <h4 class="title">Epidermal growth factor receptors and EOC</h4> <p>The epidermal growth factor receptor (EGFR or ErbB1) is a cell surface molecule that is normally involved in controlling cell growth. The EGFR is a tyrosine kinase enzyme that is made up of an extracellular ligand‐binding domain, a cell membrane‐spanning region, and an intracellular tyrosine kinase domain (<a href="#CD007927-fig-0001">Figure 1</a>A). Following binding of its ligand, epidermal growth factor (EGF), the EGFR is activated; EGFR tyrosine kinase activity phosphorylates tyrosine residues on the EGFR and on other proteins (<a href="#CD007927-fig-0001">Figure 1</a>B), causing their activation and precipitating a sequence of downstream events that lead to increased cell growth (<a href="#CD007927-fig-0001">Figure 1</a>C). EGFR was first implicated in cancer aetiology when it was discovered that an oncogenic retrovirus encoded a mutated version of <i>EGFR</i> (<a href="./references#CD007927-bbs2-0062" title="DownwardJ , YardenY , MayesE , ScraceG , TottyN , StockwellP , et al. Close similarity of epidermal growth factor receptor and v‐erb‐B oncogene protein sequences. Nature1984;307(5951):521‐7. ">Downward 1984</a>). Abnormal EGFR activation has been demonstrated in EOC, is associated with a poorer prognosis (<a href="./references#CD007927-bbs2-0081" title="NicholsonRI , GeeJM , HarperME . EGFR and cancer prognosis. European Journal of Cancer2001;37(Suppl 4):S9‐15. ">Nicholson 2001</a>), and can happen through a variety of mechanisms. <i>EGFR</i> mutation occurs in some cases of EOC (<a href="./references#CD007927-bbs2-0077" title="MoscatelloDK , Holgado‐MadrugaM , GodwinAK , RamirezG , GunnG , ZoltickPW , et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Research1995;55(23):5536‐9. ">Moscatello 1995</a>); the most common <i>EGFR</i> mutation is seen in the extracellular region and has been shown to result in EGF‐independent activation (<a href="./references#CD007927-bbs2-0063" title="EkstrandAJ , SugawaN , JamesCD , CollinsVP . Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N‐ and/or C‐terminal tails. Proceedings of the National Academy of Science USA1992;89(10):4309‐13. ">Ekstrand 1992</a>). Overexpression of EGFR is common in many cancers (<a href="./references#CD007927-bbs2-0051" title="BartlettJM , LangdonSP , SimpsonBJ , StewartM , KatsarosD , SismondiP , et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. British Journal of Cancer1996;73(3):301‐6. ">Bartlett 1996</a>; <a href="./references#CD007927-bbs2-0087" title="SlamonDJ , GodolphinW , JonesLA , HoltJA , WongSG , KeithDE , et al. Studies of the HER‐2/neu proto‐oncogene in human breast and ovarian cancer. Science1989;244(4905):707‐12. ">Slamon 1989</a>). EGFR activity can also be stimulated by increased production of EGF by tumour cells (<a href="./references#CD007927-bbs2-0050" title="BanderaCA , TsuiHW , MokSC , TsuiFW . Expression of cytokines and receptors in normal, immortalized, and malignant ovarian epithelial cell lines. Anticancer Research2003;23(4):3151‐7. ">Bandera 2003</a>). EGFR is central to the promotion of cell growth and has a role in the development of cancer. Therefore, preventing EGFR activity could be an attractive target for novel therapeutic agents. Anti‐EGFR agents have been developed to prevent extracellular EGF binding or to inhibit tyrosine kinase activity (<a href="#CD007927-fig-0001">Figure 1</a>D). EGFR is a member of a family of similar molecules called 'the epidermal growth factor receptor family'. This family also includes human epidermal growth factor receptor (HER2/neu), Erb3 and Erb4. </p> <div class="figure" id="CD007927-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="(A) The EGFR is a transmembrane protein. (B) Following binding to its ligand, EGF, the EGFR is stimulated and develops tyrosine kinase activity. (C) Tyrosine kinase activity sets off a sequence of downstream events that lead to stimulation of cell growth. (D) EGFR activity can be blocked by antibodies that prevent EGF binding to the receptor or by use of chemicals that inhibit tyrosine kinase enzyme activity." data-id="CD007927-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>(A) The EGFR is a transmembrane protein. (B) Following binding to its ligand, EGF, the EGFR is stimulated and develops tyrosine kinase activity. (C) Tyrosine kinase activity sets off a sequence of downstream events that lead to stimulation of cell growth. (D) EGFR activity can be blocked by antibodies that prevent EGF binding to the receptor or by use of chemicals that inhibit tyrosine kinase enzyme activity. </p> </div> </div> </div> </section> <section id="CD007927-sec-0042"> <h4 class="title">EGFR tyrosine kinase inhibitors</h4> <p>Clinical trials have evaluated several small molecule inhibitors of the EGFR tyrosine kinase for treatment of EOC, including gefitinib and erlotinib. </p> <p>Gefitinib (Iressa/ZD1839) is a small molecule that specifically inhibits EGFR tyrosine kinase activity (<a href="./references#CD007927-bbs2-0078" title="MoulderSL , YakesFM , MuthuswamySK , BiancoR , SimpsonJF , ArteagaCL . Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)‐over expressing breast cancer cells in vitro and in vivo. Cancer Research2001;61(24):8887‐95. ">Moulder 2001</a>). Preclinical studies have shown antitumour activity (<a href="./references#CD007927-bbs2-0056" title="CiardielloF , CaputoR , BiancoR , DamianoV , FontaniniG , CuccatoS , et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical Cancer Research2001;7(5):1459‐65. ">Ciardiello 2001</a>), and a phase I clinical trial showed that the orally active agent was well tolerated by patients with a range of tumour types, including ovarian (<a href="./references#CD007927-bbs2-0053" title="BaselgaJ , RischinD , RansonM , CalvertH , RaymondE , KiebackDG , et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Journal of Clinical Oncology2002;20(21):4292‐302. ">Baselga 2002</a>). A phase II study of gefitinib demonstrated poor response rates in women with platinum‐resistant EOC who had not had the EGFR status of their EOC tested (<a href="./references#CD007927-bbs2-0039" title="PosadasEM , LielMS , KwitkowskiK , MinasianL , GodwinK , HussainMM , et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian tumors. Cancer2007;109(7):1323‐30. ">Posadas 2007</a>). However, a 9% response rate reported in participants with EGFR‐positive tumours highlighted the need for selecting patients likely to benefit from treatment (<a href="./references#CD007927-bbs2-0041" title="Gynecologic Oncology Group, National Cancer Institute. A Phase II Trial of ZD1839 (Iressa) (NSC# 715055) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma. ClinicalTrials.gov Identifier: NCT00023699. Protocol registered at ClinicalTrials.gov on 13 September 2001. SchilderRJ , SillMW , ChenX , DarcyKM , DecesareSL , LewandowskiG , et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of EGFR mutations and immunohistochemical expression: a gynecologic oncology group study. Clinical Cancer Research2005;11(15):5539‐48. ">Schilder 2005</a>). Although response rates were modest, treatment was well tolerated, and rash and diarrhoea were the main toxicities. </p> <p>Erlotinib (Tarceva/OSI‐774), another EGFR tyrosine kinase inhibitor, has been through phase I and II clinical trials. Results from a previous phase II trial suggest that erlotinib may show activity in ovarian carcinoma (<a href="./references#CD007927-bbs2-0020" title="GordonAN , FinklerN , EdwardsP , GarciaAA , CrozierM , IrwinDH , et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. International Journal of Gynecological Cancer2005;15:785‐92. ">Gordon 2005</a>). Researchers who gave erlotinib to 34 participants with EGFR‐positive recurrent, refractory, chemotherapy‐resistant EOC reported that responses were modest, but the treatment was well tolerated. Further phase II and phase III trials for erlotinib have been performed since the first version of this review was performed (<a href="./references#CD007927-bbs2-0079" title="NCT00263822 . A Randomized, Multicenter, Phase III Study of Erlotinib versus Observation in Patients With No Evidence of Disease Progression After First Line, Platinum‐Based Chemotherapy for High‐Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer. MetaRegister of Controlled Trials2005. ">NCT00263822</a>; <a href="./references#CD007927-bbs2-0080" title="NCT00520013 . A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer &amp; Papillary Serous Mullerian Tumors. MetaRegister of Controlled Trials2007. ">NCT00520013</a>). </p> <p>Neither gefitinib nor erlotinib has been licenced for use in EOC, outside of clinical trials. However, both agents have shown promise in treating other types of cancer: gefitinib has been licenced by the Food and Drug Administration (FDA) in the USA for use in certain types of non‐small cell lung cancer (NSCLC), and erlotinib has been licenced by both the FDA and the European Medicines Agency (EMEA) for use in some types of NSCLC and in pancreatic cancer. </p> </section> <section id="CD007927-sec-0043"> <h4 class="title">Antibodies against EGFR</h4> <p>It is also possible to block the EGFR pathway by using specific antibodies.</p> <p>Monoclonal antibodies have a specific target pattern to which they bind. Monoclonal antibodies have been developed against the extracellular portion of EGFR (<a href="#CD007927-fig-0001">Figure 1</a>D). These antibodies can reduce EGFR activity, either by directly blocking EGF binding, or by causing the EGFR to be taken into the cell and degraded, thereby reducing the number of receptors available for stimulation at the cell surface. The monoclonal antibodies developed for clinical trials are humanised. This means that in addition to binding to the EGFR, a portion of these antibodies are identical to normal human antibodies, so they can stimulate the patient's own immune system. When the antibody binds to the EGFR on a cell, it labels the cancer cell so that it is recognised as foreign and is then destroyed by cells of the patient's own immune system. HER‐2/neu is another member of the EGFR family, and overexpression is related to poor outcomes in breast cancer. A monoclonal antibody, trastuzumab (Herceptin), has been developed that binds to HER‐2/neu (<a href="./references#CD007927-bbs2-0052" title="BaselgaJ , AlbanellJ , MolinaMA , ArribasJ . Mechanism of action of trastuzumab and scientific update. Seminars in Oncology2001;28(5 Suppl 16):4‐11. ">Baselga 2001</a>; <a href="./references#CD007927-bbs2-0057" title="CooleyS , BurnsLJ , RepkaT , MillerJS . Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody‐dependent cellular cytotoxicity against LFA‐3 and HER2/neu. Experimental Hematology1999;27(10):1533‐41. ">Cooley 1999</a>). <a href="./references#CD007927-bbs2-0011" title="BookmanMA , DarcyKM , Clarke‐PearsonD , BoothbyRA , HorowitzIR . Evaluation of monoclonal humanized anti‐HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2003;21:283‐90. ">Bookman 2003</a> reported a 7.3% response rate with no significant toxicity among women with recurrent EOC treated with Herceptin (<a href="./references#CD007927-bbs2-0011" title="BookmanMA , DarcyKM , Clarke‐PearsonD , BoothbyRA , HorowitzIR . Evaluation of monoclonal humanized anti‐HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2003;21:283‐90. ">Bookman 2003</a>). Another monoclonal antibody, pertuzumab, prevents dimerisation of HER‐2 with other HER receptors, and clinical trials have used pertuzumab to treat women with EOC (<a href="./references#CD007927-bbs2-0021" title="GenentechInc . A Phase II, Open‐label, Multicenter Study to Evaluate the Effect of Tumor‐based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced, Refractory or Recurrent Ovarian Cancer. ClinicalTrials.gov identifier: NCT00058552. Protocol registered at ClinicalTrials.gov on 8 April 2003. GordonMS , MateiD , AghajanianC , MatulonisUA , BrewerM , FlemingGF , et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. Journal of Clinical Oncology2006;24:4324‐32. ">Gordon 2006</a>; <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>). </p> <p>IMC‐C225 (Cetuximab/Erbitux) is a humanised mouse monoclonal antibody against EGFR (HER‐1/ErbB1) that has shown activity in combination with topotecan (a conventional chemotherapeutic agent) in preclinical studies (<a href="./references#CD007927-bbs2-0055" title="CiardielloF , BiancoR , DamianoV , DeLorenzoS , PepeS , DePlacidoS , et al. Antitumor activity of sequential treatment with topotecan and anti‐epidermal growth factor receptor monoclonal antibody C225. Clinical Cancer Research1999;5(4):909‐16. ">Ciardiello 1999</a>; <a href="./references#CD007927-bbs2-0068" title="GoldsteinNI , PrewettM , ZuklysK , RockwellP , MendelsohnJ . Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clinical Cancer Research1995;1(11):1311‐8. ">Goldstein 1995</a>). Cetuximab binds to the EGFR and blocks EGF binding, thereby preventing downstream signalling and growth stimulation, as well as antibody‐directed cell killing by the immune system. </p> </section> </section> <section id="CD007927-sec-0044"> <h3 class="title" id="CD007927-sec-0044">Why it is important to do this review</h3> <p>Novel types of treatment strategies work in different ways when compared with conventional chemotherapeutic agents. Therefore, it is important to establish whether adding these new drugs to conventional chemotherapy regimens yields added benefit in terms of survival, and, if so, at what cost, in terms of additional harmful effects. Furthermore, these compounds may be less toxic than conventional chemotherapy agents; therefore it may be possible to give these newer treatments to women who are not currently taking chemotherapy (so called maintenance treatment) to reduce the chance of, or to delay, recurrence of their EOC. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007927-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007927-sec-0045">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007927-sec-0155">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007927-sec-0045"></div> <p>To compare the effectiveness and harmful effects of interventions that target the epidermal growth factor receptor in the treatment of epithelial ovarian cancer (EOC). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007927-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007927-sec-0046">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007927-sec-0156">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007927-sec-0046"></div> <section id="CD007927-sec-0047"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007927-sec-0048"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD007927-sec-0049"> <h4 class="title">Types of participants</h4> <p>Adult women with histologically proven EOC<i>.</i> We excluded women with other concurrent malignancies. </p> </section> <section id="CD007927-sec-0050"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD007927-list-0001"> <li> <p>Anti‐EGFR agents (tyrosine kinase inhibitors and/or monoclonal antibodies) + conventional chemotherapy versus conventional chemotherapy </p> </li> <li> <p>Anti‐EGFR agents (tyrosine kinase inhibitors and/or monoclonal antibodies) versus no treatment </p> </li> </ul> </p> </section> <section id="CD007927-sec-0051"> <h4 class="title">Types of outcome measures</h4> <section id="CD007927-sec-0052"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007927-list-0002"> <li> <p>Overall survival: survival until death from all causes</p> </li> </ul> </p> </section> <section id="CD007927-sec-0053"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007927-list-0003"> <li> <p>Progression‐free survival</p> </li> <li> <p>Quality of life, measured by a validated scale</p> </li> <li> <p>Toxicity: grades of toxicity to be extracted and grouped as follows ‐ see <a href="./references#CD007927-bbs2-0059" title="Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf2017. ">CTEP 2017</a> </p> <ul id="CD007927-list-0004"> <li> <p>Haematological (leucopenia, anaemia, thrombocytopenia, neutropaenia, haemorrhage)</p> </li> <li> <p>Gastrointestinal (nausea, vomiting, anorexia, diarrhoea, liver, proctitis)</p> </li> <li> <p>Genitourinary</p> </li> <li> <p>Skin (stomatitis, mucositis, alopecia, allergy)</p> </li> <li> <p>Neurological (peripheral and central)</p> </li> <li> <p>Other side effects not categorised above.</p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD007927-sec-0054"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for papers written in all languages and carried out translations when necessary. </p> <section id="CD007927-sec-0055"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases.</p> <p> <ul id="CD007927-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 8), in the Cochrane Library; </p> </li> <li> <p>MEDLINE via Ovid (October 2010 to August week 4, 2017);</p> </li> <li> <p>Embase via Ovid (October 2010 to 2017, week 36).</p> </li> </ul> </p> <p>We have presented the CENTRAL, MEDLINE, and Embase search strategies related to the review topic in <a href="./appendices#CD007927-sec-0128">Appendix 1</a>, <a href="./appendices#CD007927-sec-0129">Appendix 2</a>, and <a href="./appendices#CD007927-sec-0130">Appendix 3</a>, respectively. </p> <p>We searched the databases from 1990 until September 2017. These novel agents have been developed recently, and so searches before 1990 would not have been relevant. </p> <p>We identified all relevant articles on PubMed and, by using the 'related articles' feature, we carried out a further search for newly published articles. </p> </section> <section id="CD007927-sec-0056"> <h4 class="title">Searching other resources</h4> <p>We searched <a href="https://www.cancer.gov/publications/pdq" target="_blank">Physicians Data Query</a>, <a href="http://www.isrctn.com/" target="_blank">ISRCTN registry</a><a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>, <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" target="_blank">National Cancer Institute Clinical Trials Information</a>, and the <a href="https://sites.google.com/a/york.ac.uk/yhectrialsregisters/home/researchregisters/uk-national-research-register-1" target="_blank">National Research Register</a> (NRR) for ongoing trials. We sought details of ongoing or unpublished trials from the <a href="https://www.fda.gov/" target="_blank">FDA</a> (Food and Drug Administration, the regulatory body for medicines within the USA) and <a href="http://www.ema.europa.eu/ema/" target="_blank">EMEA</a> (European Medicines Agency, the drug regulatory body within Europe), and from pharmaceutical company sources. </p> <p>We searched the reference lists of all included trials for further relevant trials.</p> <section id="CD007927-sec-0057"> <h5 class="title">Correspondence</h5> <p>We contacted the authors of relevant trials to ask for clarification and for further data, which may or may not have been published, and we requested further information from pharmaceutical companies involved in the development of anti‐EGFR agents. </p> </section> </section> </section> <section id="CD007927-sec-0058"> <h3 class="title" id="CD007927-sec-0058">Data collection and analysis</h3> <section id="CD007927-sec-0059"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to the reference management database <i>Endnote</i> and removed duplicates. At least two review authors (a combination from KG, CT, KH, TL, RG, and JM) independently examined the remaining 6105 unique references (4103 in searches for the original review and 2002 from updated searches). We identified another 15 records from the grey literature. We excluded studies that clearly did not meet the inclusion criteria, and we obtained full‐text copies of 54 potentially relevant references (20 from the original review). At least two review authors (a combination of KG, KH, RG, TL, JM, and CT) independently assessed the eligibility of retrieved papers and excluded 42 references. The two review authors resolved disagreements by discussion and, when necessary, by consultation with a third review author (JM). We have documented reasons for exclusion in the <a href="./references#CD007927-sec-0146" title="">Characteristics of excluded studies</a> table. For the original review, we identified five ongoing studies through searches of the grey literature, but all had been published in the most recent search, at least in abstract form. In the original review, three studies were ongoing; all were subsequently published and are now among the <a href="#CD007927-sec-0076">Included studies</a> in this updated review. We have included a total of seven studies in the review, and we have detailed study characteristics in the <a href="./references#CD007927-sec-0145" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD007927-sec-0060"> <h4 class="title">Data extraction and management</h4> <p>For included studies, we abstracted data as follows.</p> <p> <ul id="CD007927-list-0006"> <li> <p>Author, year of publication, and journal citation (including language).</p> </li> <li> <p>Country.</p> </li> <li> <p>Setting.</p> </li> <li> <p>Inclusion and exclusion criteria.</p> </li> <li> <p>Study design and methods.</p> </li> <li> <p>Study population.</p> <ul id="CD007927-list-0007"> <li> <p>Total number enrolled.</p> </li> <li> <p>Characteristics.</p> </li> <li> <p>Age.</p> </li> <li> <p>Comorbidities.</p> </li> <li> <p>Previous treatment.</p> </li> </ul> </li> <li> <p>Total study duration.</p> </li> <li> <p>Total number of intervention groups.</p> </li> <li> <p>EOC details at diagnosis.</p> <ul id="CD007927-list-0008"> <li> <p>International Federation of Obstetrics and Gynecology (FIGO) stage.</p> </li> <li> <p>Histological cell type.</p> </li> <li> <p>Tumour grade.</p> </li> <li> <p>Extent of disease.</p> </li> </ul> </li> <li> <p>Intervention details.</p> <ul id="CD007927-list-0009"> <li> <p>Type of EGFR inhibitor.</p> </li> <li> <p>Dose.</p> </li> <li> <p>Duration of treatment.</p> </li> <li> <p>Consolidation treatment or treatment of active disease.</p> </li> </ul> </li> <li> <p>Comparison details.</p> <ul id="CD007927-list-0010"> <li> <p>Type of control: conventional chemotherapy or no treatment.</p> </li> <li> <p>Dose (if appropriate).</p> </li> <li> <p>Duration (if appropriate).</p> </li> </ul> </li> </ul> <ul id="CD007927-list-0011"> <li> <p>Deviations from protocol.</p> </li> <li> <p>Risk of bias in the study (see below).</p> </li> <li> <p>Duration of follow‐up.</p> </li> <li> <p>Outcomes: overall survival, progression‐free survival, quality of life, toxicity.</p> <ul id="CD007927-list-0012"> <li> <p>For each outcome: outcome definition (with diagnostic criteria if relevant).</p> </li> <li> <p>Unit of measurement (if relevant).</p> </li> <li> <p>For scales: upper and lower limits, and whether high or low score is good.</p> </li> <li> <p>Results: number of participants allocated to each intervention group.</p> </li> <li> <p>For each outcome of interest: sample size; missing participants.</p> </li> </ul> </li> </ul> </p> <p>We extracted data on outcomes as below.</p> <p> <ul id="CD007927-list-0013"> <li> <p>For time‐to‐event (overall survival and progression‐free survival) data, we extracted the log of the hazard ratio [log(HR)] and its standard error from trial reports; if these were not reported, we attempted to estimate them from other reported statistics using the methods of <a href="./references#CD007927-bbs2-0083" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998.</a>  </p> </li> <li> <p>For dichotomous outcomes (toxicity), we extracted the number of participants in each treatment arm who experienced the outcome of interest and the number of participants assessed at endpoint, to estimate a risk ratio (RR). </p> </li> </ul> </p> <p>We extracted both unadjusted and adjusted statistics, if reported. When we extracted adjusted results, we recorded the variables that were adjusted. </p> <p>When possible, all extracted data were those relevant to an intention‐to‐treat analysis, in which participants were analysed in the groups to which they were assigned. </p> <p>We noted the time points at which outcomes were collected and reported.</p> <p>Two review authors (KH and KG) abstracted data independently onto a data abstraction form specially designed for the review. We resolved differences by discussion, or by appeal to a third review author (JM or SN) when necessary. </p> </section> <section id="CD007927-sec-0061"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Cochrane tool to assess risk of bias in included RCTs. This included assessment of: </p> <p> <ul id="CD007927-list-0014"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants, treatment providers, and outcome assessors;</p> </li> <li> <p>incomplete outcome data: we recorded the proportion of participants whose outcomes were not reported at the end of the study; we noted whether loss to follow‐up was not reported. We coded a satisfactory level of loss to follow‐up for each outcome as: </p> </li> </ul> <ul class="plain" id="CD007927-list-0015"> <li> <ul id="CD007927-list-0016"> <li> <p>yes, if less than 20% of participants were lost to follow‐up and reasons for loss to follow‐up were similar in both treatment arms; </p> </li> <li> <p>no, if more than 20% of participants were lost to follow‐up or reasons for loss to follow‐up differed between treatment arms; and </p> </li> <li> <p>unclear; if loss to follow‐up was not reported</p> </li> </ul> </li> </ul> <ul id="CD007927-list-0017"> <li> <p>selective reporting of outcomes; and</p> </li> <li> <p>other possible sources of bias.</p> </li> </ul> </p> <p>Two review authors (CT and KG) independently applied the risk of bias tool and resolved differences by discussion or by appeal to a third review author (JM). We have presented these results in a risk of bias summary table. We have interpreted these results in the light of findings with respect to risk of bias. </p> </section> <section id="CD007927-sec-0062"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following measures of the effects of treatment.</p> <p> <ul id="CD007927-list-0018"> <li> <p>For time‐to‐event data, we used the hazard ratio (HR).</p> </li> <li> <p>For dichotomous outcomes, we used the risk ratio (RR). However, we were unable to estimate an RR for comparison of treatments if one or both treatment groups experienced no events, as in skin toxicity and congestive heart failure outcomes. </p> </li> </ul> </p> <p>When adjusted results were available, we preferred to use them; otherwise we used unadjusted results. </p> </section> <section id="CD007927-sec-0063"> <h4 class="title">Unit of analysis issues</h4> <p>The units of analysis were the participants receiving interventions of interest.</p> </section> <section id="CD007927-sec-0064"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute missing outcome data for any outcomes. If data were missing or only imputed data were reported, we contacted trial authors to request data on outcomes only among participants who were assessed. </p> </section> <section id="CD007927-sec-0065"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between studies by visually inspecting forest plots, by estimating the percentage of heterogeneity between trials that cannot be ascribed to sampling variation (<a href="./references#CD007927-bbs2-0072" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>), by performing a formal statistical test of the significance of the heterogeneity (<a href="./references#CD007927-bbs2-0060" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , Davey SmithG , AltmanDG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001. ">Deeks 2001</a>), and, when possible, by conducting subgroup analyses (see below). If we found evidence of substantial heterogeneity, we investigated and reported possible reasons for this. </p> </section> <section id="CD007927-sec-0066"> <h4 class="title">Assessment of reporting biases</h4> <p>We had planned to use funnel plots to investigate possible reporting bias and the presence of small‐study effects. However, we did not produce funnel plots due to the limited number of studies per outcome (i.e. fewer than 10) (<a href="./references#CD007927-bbs2-0071" title="GuyattGH , OxmanAD , MontoriM , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence ‐ publication bias. Journal of Clinical Epidemiology2011;64(12):1277‐82. ">Guyatt 2011</a>). </p> </section> <section id="CD007927-sec-0067"> <h4 class="title">Data synthesis</h4> <p>We pooled results of clinically similar studies in meta‐analyses.</p> <p> <ul id="CD007927-list-0019"> <li> <p>For time‐to‐event data, we pooled HRs by using the generic inverse variance facility of RevMan 5. </p> </li> <li> <p>For dichotomous outcomes, we calculated and pooled the RR for each study.</p> </li> <li> <p>For continuous outcomes, we would have pooled mean differences between treatment arms at the end of follow‐up if trials had measured the outcome on the same scale; otherwise we would have pooled standardised mean differences. </p> </li> </ul> </p> <section id="CD007927-sec-0068"> <h5 class="title">Assessing the certainty of the evidence</h5> <p>The GRADE method was introduced following publication of the initial protocol, and we included it in this update as an a priori analysis to meet current MECIR guidelines (<a href="./references#CD007927-bbs2-0069" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐4. ">GRADE Working Group</a>). Two review authors independently exported data into the GRADEpro Guideline Development Tool and analysed them using GRADE methods, with reference to a third review author to reach consensus when disagreements arose (<a href="./references#CD007927-bbs2-0070" title="GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. Hamilton (ON): McMaster University,2015. Developed by Evidence Prime, Inc. ">GRADEpro GDT</a>; <a href="./references#CD007927-bbs2-0085" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook. ">Schünemann 2014</a>). </p> <p>We downgraded the evidence from 'high' certainty by one level for serious (or by two levels for very serious) concerns for each limitation. </p> <p> <ul id="CD007927-list-0020"> <li> <p>High‐certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate‐certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low‐certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low‐certainty: w<i>e</i> have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>Certainty of evidence could be upgraded for large magnitude of effect if all plausible confounding would reduce or increase the demonstrated effect, if no effect was observed, or if a dose‐response effect was noted. </p> <p>We summarised data in a 'Summary of findings' table that included the most important outcome data: overall survival and progression‐free survival for primary disease and recurrent disease, and any G3‐4 toxicity (subdivided by treatment type). As the current GRADEpro software does not allow data reported as hazard ratios, we analysed survival at time points for overall survival and progression‐free survival, when data allowed. </p> </section> </section> <section id="CD007927-sec-0069"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had not originally planned to conduct subgroup analyses. However, we did perform subgroup analyses based on type of anti‐EGFR treatment (tyrosine kinase inhibitor vs monoclonal antibody) because these treatments may have involved different activities and varying side effect profiles, given their different mechanisms of action. We performed analyses separately for primary treatment and for treatment of recurrent disease. We also performed subgroup analyses based on platinum resistance/sensitivity in recurrent disease because biologically these often yield response rates that are different from those seen with conventional treatment. When visual inspection of forest plots revealed obvious heterogeneity between individual anti‐EGFR agents for the same type of anti‐EGFR treatment, we also performed subgroup analyses (see <a href="#CD007927-sec-0138">Differences between protocol and review</a> section). </p> </section> <section id="CD007927-sec-0070"> <h4 class="title">Sensitivity analysis</h4> <p>We performed no sensitivity analyses (see <a href="#CD007927-sec-0138">Differences between protocol and review</a> section) due to the small number of studies included in each group<b>.</b> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007927-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007927-sec-0071"></div> <section id="CD007927-sec-0072"> <h3 class="title">Description of studies</h3> <section id="CD007927-sec-0073"> <h4 class="title">Results of the search</h4> <section id="CD007927-sec-0074"> <h5 class="title">Original review: up to 2011</h5> <p>The original search (October 2010) for the previously published version of this review revealed 4103 unique references. Through title and abstract screening of these references, review authors identified 20 trials as potentially eligible for inclusion in the review. Upon full‐text screening of these 20 references, 19 studies were excluded for the reasons described in the <a href="./references#CD007927-sec-0146" title="">Characteristics of excluded studies</a> table. A single RCT met review inclusion criteria, and this study was described in the <a href="./references#CD007927-sec-0145" title="">Characteristics of included studies</a> table (<a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>). </p> <p>Searches of the grey literature at that stage yielded three relevant ongoing trials and eight other studies that, for the reasons described, were included in the <a href="./references#CD007927-sec-0146" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD007927-sec-0075"> <h5 class="title">Review update: 2011 to 2017</h5> <p>We updated the search in August 2017. We de‐duplicated the results of this search in Endnote and uploaded the references into <a href="./references#CD007927-bbs2-0058" title="Covidence systematic review software, Veritas Health Innovation. www.covidence.org. Melbourne, Australia. ">Covidence</a> systematic review software to aid sifting of titles and abstracts. We initially identified an additional 2002 references and five from the grey literature. Upon title and abstract screening, we excluded all but 34 references. We screened the full‐text articles and excluded 23 for reasons given in the <a href="./references#CD007927-sec-0146" title="">Characteristics of excluded studies</a> table. We identified eight references that were duplicates of studies identified in the previous search. We included seven studies from the remaining 28 references (<a href="./references#CD007927-sec-0145" title="">Characteristics of included studies</a>). Three of these studies corresponded with the three references identified as ongoing studies in the original review. </p> <p>In summary, we screened a total of 6120 references (6105 from searches and 15 from grey literature). We excluded 6039 studies on title and abstract screening, and another 42 unique references after review of the full texts. We included seven studies (32 references ‐ 24 unique and eight duplicates) that met our inclusion criteria (<a href="#CD007927-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD007927-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007927-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> </section> <section id="CD007927-sec-0076"> <h4 class="title">Included studies</h4> <p>Seven studies (24 references) including 1725 women met the inclusion criteria, and we included them in our analysis (<a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>; <a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a>; <a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>; <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>; <a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>; <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>; <a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>). </p> <section id="CD007927-sec-0077"> <h5 class="title">Participants</h5> <p>All studies were limited to adult women with histologically proven epithelial ovarian, primary peritoneal, or fallopian tube cancer. </p> <section id="CD007927-sec-0078"> <h6 class="title">First‐line treatment</h6> <p><a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a> included 835 women who had completed first‐line chemotherapy within six weeks and was therefore a maintenance and consolidation study after first‐line treatment. This trial excluded women with platinum‐refractory disease (growth of cancer despite platinum‐based chemotherapy). Participants were not selected for tumour EGFR expression. Median age was 59 years (range 19 to 85) in the erlotinib group, and 59 years (range 27 to 84) in the observation arm. </p> </section> <section id="CD007927-sec-0079"> <h6 class="title">Treatment for recurrent disease</h6> <p>The other six studies enrolled 890 women with relapsed disease (one patient was subsequently excluded) (<a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>; <a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a>; <a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>; <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>; <a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>; <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>). </p> <p><a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a> was an open‐label study that randomised 102 women and included 96 in the final analysis. Study authors have presented data in a conference proceedings abstract only, and so reasons for the loss of six participants are unclear. Eligible women had platinum‐sensitive relapsed epithelial ovarian/fallopian or peritoneal cancer and had received no more than two prior treatments for this disease. Inclusion criteria included a requirement to have measurable disease or elevated cancer antigen (CA)‐125 and to have <i>KRAS</i> wild type on tumour biopsy. </p> <p><a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a> included 129 women with recurrent EOC who were previously treated with at least one cycle of platinum‐based chemotherapy and could have received up to three previous cycles of chemotherapy, including previous antiangiogenic agents. Other inclusion criteria included a performance status showing Zubrod score 0 to 2 and adequate haematological, renal, liver, and cardiovascular function. Median age was 61.7 years (range 32.6 to 80) in the control group and 61.9 years (range 34.3 to 82.5) in the study group. </p> <p><a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a> included 149 women at first relapse, although all women had platinum‐sensitive disease (progression‐free interval greater than 6 months after completion of a platinum‐based regimen). Other requirements included Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and adequate haematological, renal, hepatic, and cardiac function. Median age was 58 years (range 18 to 81) in the pertuzumab group and 58 years (range 18 to 85 years) in the placebo group. </p> <p><a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a> included 156 women with platinum‐resistant or platinum‐refractory EOC and low tumour HER‐3 mRNA expression. Originally 324 women were enrolled, but researchers excluded 156 due to ineligibility, including failure of testing and central review of pathology or after HER‐3 tumour testing. </p> <p><a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a> included 223 women with platinum‐resistant or ‐refractory advanced EOC. Participants underwent mandatory pretreatment core needle biopsy and submitted archived tumour samples, as available, for biomarker analysis (heregulin (HRG); human epidermal growth factor receptor (HER‐3 (ErbB3); HER‐2; EGFR; and betacellulin (BTC)). Median age was 58.5 years (range 30 to 82) for seribantumab plus paclitaxel (S + P) and 60.6 years (range 28 to 85) for paclitaxel only (P). </p> <p><a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a> included 131 women and assessed 130 (99%) of them at the end of the trial. All women had previously been treated with at least one platinum‐containing chemotherapy regimen and were now platinum‐resistant. All women had ECOG performance status of 0 or 1, left ventricular ejection fraction 50% or higher, and adequate haematological, renal, and hepatic function. All women had platinum‐resistant or platinum‐refractory cancer and measurable disease as per Response Evaluation Criteria in Solid Tumours (RECIST), or clinically or radiologically detectable disease with two consecutive rising CA‐125 levels before treatment. None had received more than one prior treatment for platinum‐resistant disease, but participants could have received any number of platinum‐containing regimens before becoming platinum‐resistant. No participants had received prior treatment with any HER‐2 pathway inhibitors or gemcitabine. </p> </section> </section> <section id="CD007927-sec-0080"> <h5 class="title">Interventions</h5> <section id="CD007927-sec-0081"> <h6 class="title">First‐line treatment</h6> <p><a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a> was an open‐label phase III RCT that randomised women to either maintenance erlotinib (EGFR tyrosine kinase inhibitor) 150 mg orally daily for two years (or until disease progression) or observation (not placebo controlled) following response to first‐line platinum‐based chemotherapy. </p> </section> <section id="CD007927-sec-0082"> <h6 class="title">Treatment for recurrent disease</h6> <p><a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a> was an open‐label study of carboplatin AUC4 and gemcitabine 1000 mg/m² or carboplatin AUC5 and pegylated doxorubicin 40 mg/m²; trialists randomised women to panitumumab 6 mg/kg day 1 and day 15, every three or four weeks. Panitumumab is a fully human monoclonal antibody specific to the epidermal growth factor receptor (EGFR). </p> <p><a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a> was an open‐label randomised phase II study that compared a combination of docetaxel and vandetanib (D + V) versus docetaxel (D) alone in women with recurrent EOC. Women whose condition progressed on docetaxel (D) were allowed to cross over to single‐agent vandetanib (V). Vandetanib is an oral tyrosine kinase inhibitor that is not a 'pure' EGFR inhibitor but inhibits several tyrosine kinases involved in malignancy: vascular epithelial growth factor receptor 2/3 (VEGFR 2/3), EGFR, and EGFR rearranged during transfection transmembrane receptor tyrosine kinase, which is known as RET. The rationale for vandetanib is that the action of VEGFR inhibitors is thought to be blunted by EGFR signalling, and combined VEGFR/EGFR inhibitors had demonstrated activity in preclinical models of EOC (<a href="./references#CD007927-bbs2-0091" title="WedgeSR , OgilvieDJ , DukesM , KendrewJ , ChesterR , JacksonJA , et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Research2002;62(16):4645‐55. ">Wedge 2002</a>). </p> <p><a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a> was an open‐label phase II RCT that randomised women to either chemotherapy (carboplatin with paclitaxel or gemcitabine) or chemotherapy and pertuzumab (840‐mg loading dose followed by 420 mg three times weekly). After completion or withdrawal of chemotherapy (if toxicity), pertuzumab was continued three times weekly for another 11 cycles (17 in total) but could be continued for up to a maximum of 52 cycles. No cross‐over was allowed at any stage. </p> <p><a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a> was a double‐blind, placebo‐controlled, randomised phase III trial that compared chemotherapy plus either pertuzumab (840‐mg loading dose followed by 420 mg every three weeks) or placebo. </p> <p><a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a> examined the activity of pertuzumab, an antibody that prevents human EGFR‐2 (HER‐2) dimerisation with other EGFR monomers ‐ a process required for activation and signalling. This randomised double‐blind phase II study randomly assigned women to receive gemcitabine (800 mg/m² on days 1 and 8 of a 21‐day cycle) plus either placebo or pertuzumab (840‐mg loading dose administered intravenously followed by 420 mg every three weeks). Treatment was administered until disease progression or unacceptable toxicity was evident. Kaplan‐Meier plots show that maximum length of follow‐up was 30 months. </p> <p><a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a> was an open‐label study of seribantumab, a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER)‐3 (ErbB3). Antibody binding blocks heregulin (HRG)–mediated ErbB3 signalling and induces ErbB3 receptor downregulation. Women with platinum‐resistant or ‐refractory disease received paclitaxel plus/minus seribantumab. Paclitaxel was given weekly (80 mg/m² during cycle one, with optional modification in subsequent cycles) once per week for three weeks, followed by one week of rest. Seribantumab was given as a 40‐mg/kg loading dose, then at 20 mg/kg once weekly. </p> </section> </section> <section id="CD007927-sec-0083"> <h5 class="title">Outcomes</h5> <p>Progression‐free survival and overall survival were the primary or secondary outcomes in all studies. Most studies also reported adverse events using Common Terminology Criteria for Adverse Events version 5.0 (<a href="./references#CD007927-bbs2-0059" title="Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf2017. ">CTEP 2017</a>) or an earlier version. Other frequently reported outcomes included overall response rate (ORR), complete response rate (CR), and partial response rate. </p> <p><a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a> evaluated quality of life as a secondary outcome by using the European Organization for Research and Treatment of Cancer core quality of life questionnaire (EORTC QLQ‐C30) (<a href="./references#CD007927-bbs2-0065" title="GiesingerJM , KiefferJM , FayersPM , GroenvoldM , PetersenMA , ScottNW , et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ‐C30 is robust. Journal of Clinical Epidemiology2016;69:79‐88. [DOI: 10.1016/j.jclinepi.2015.08.007] ">Giesinger 2016</a>). </p> <p>In a separate conference abstract (Lalla 2008, in <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>), trial investigators also reported on quality of life, as measured by the FOSI questionnaire (Functional Assessment of Cancer Therapy – Ovarian (FACT‐O) Symptom Index) (<a href="./references#CD007927-bbs2-0074" title="JensenSE , RosenbloomSK , BeaumontJL , AbernethyA , JacobsenPB , SyrjalaK , et al. A new index of priority symptoms in advanced ovarian cancer. Gynecologic Oncology2011;120(2):214‐9. ">Jensen 2011</a>). Similarly, <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a> reported quality of life data outcomes in a separate abstract (Hilpert 2016, in <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>). <a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a> incompletely reported quality of life data that were not available for analysis. </p> </section> </section> <section id="CD007927-sec-0084"> <h4 class="title">Excluded studies</h4> <p>After obtaining full‐text articles, we excluded 42 references for the following reasons.</p> <p> <ul id="CD007927-list-0021"> <li> <p>Two references were narrative review articles and did not include any study that met our inclusion criteria (<a href="./references#CD007927-bbs2-0017" title="DinhP , HarnettP , Piccart‐GebhartMJ , AwadaA . New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Critical Reviews in Oncology/Hematology2008;67:103‐12. ">Dinh 2008</a>; <a href="./references#CD007927-bbs2-0037" title="PalayekarMJ , HerzogTJ . The emerging role of epithelial growth factor receptor inhibitors in ovarian cancer. International Journal of Gynecological Cancer2008;18(5):879‐90. ">Palayekar 2008</a>). </p> </li> <li> <p>Nine references were non‐randomised phase I studies of EGFR antagonists conducted to establish maximum tolerated dose and toxicity profiles (<a href="./references#CD007927-bbs2-0009" title="BaumanJ , VerschraegenC , BelinskyS , MullerC , RutledgeT , FekrazadM , et al. A phase I study of 5‐azacytidine and erlotinib in advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology2012; Vol. 69, issue 2:547‐54. ">Bauman 2012</a>; <a href="./references#CD007927-bbs2-0013" title="CamposSM , BerlinST , ParkerLM , ChenWY , BunnellCA , AtkinsonT , et al. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. International Journal of Clinical Oncology2010; Vol. 15, issue 4:390‐8. ">Campos 2010</a>; <a href="./references#CD007927-bbs2-0025" title="HarterP , SehouliJ , KimmigR , RauJ , HilpertF , KurzederC , et al. Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO‐OVAR 2.13). Investigational New Drugs2013;31(6):1499‐504. [DOI] ">Harter 2013</a>; <a href="./references#CD007927-bbs2-0027" title="JhaveriK , MillerK , RosenL , SchneiderB , ChapL , HannahA , et al. A phase I dose‐escalation trial of trastuzumab and alvespimycin hydrochloride (KOS‐1022; 17 DMAG) in the treatment of advanced solid tumors. Clinical Cancer Research2012; Vol. 18, issue 18:5090‐8. ">Jhaveri 2012</a>; <a href="./references#CD007927-bbs2-0029" title="KimballKJ , NumnumTM , KirbyTO , ZamboniWC , EstesJM , BarnesMN , et al. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecologic Oncology2008;111:95‐101. ">Kimball 2008</a>; <a href="./references#CD007927-bbs2-0031" title="KoolenSLW , WitteveenPO , JansenRS , LangenbergMH , KronemeijerRH , NolA , et al. Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clinical Cancer Research2011; Vol. 17, issue 18:6071‐82. ">Koolen 2011</a>; <a href="./references#CD007927-bbs2-0036" title="National Cancer Institute. A Phase II Trial of Bevacizumab (NSC# 704865) and OSI‐774 (NSC# 718781) in Recurrent Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma. ClinicalTrials.gov Identifier: NCT00126542. Protocol registered at ClinicalTrials.gov on 2 August 2005. NimeiriHS , OzaAM , MorganRJ , FribergG , KaszaK , FaoroL , et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecologic Oncology2008;110(1):49‐55. ">Nimeiri 2008</a>; <a href="./references#CD007927-bbs2-0046" title="VaseyPA , GoreM , WilsonR , RustinG , GabraH , GuastallaJ‐P , et al. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. British Journal of Cancer2008;98(11):1774‐80. ">Vasey 2008</a>; <a href="./references#CD007927-bbs2-0047" title="VlahovicG , MeadowsKL , UronisHE , MorseMA , BlodeGC , RiedelRF , et al. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemotherapy &amp; Pharmacology2012; Vol. 70, issue 1:95‐102. ">Vlahovic 2012</a>). </p> </li> <li> <p>Twenty‐nine references were non‐randomised studies of single‐agent EGFR antagonists undertaken to assess response in women with EOC with or without combination conventional chemotherapy (<a href="./references#CD007927-bbs2-0008" title="AnnunziataCM , WalkerAJ , MinasianL , YuM , KotzH , WoodBJ , et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clinical Cancer Research2010;16(2):664‐72. ">Annunziata 2010</a>; <a href="./references#CD007927-bbs2-0010" title="BlankSV , ChristosP , CurtinJP , GoldmanN , RunowiczCD , SparanoJA , et al. Erlotinib added to carboplatin and paclitaxel as first‐line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecologic Oncology2010;119(3):451‐6. National Cancer Institute. A Phase II Study of OSI 774 In Combination With Carboplatin and Paclitaxel in Patients With Ovarian, Cancer of the Fallopian Tube or Primary Peritoneal Carcinoma. ClinicalTrials.gov identifier: NCT00059787. Protocol registered at ClinicalTrials.gov on 6 May 2003. ">Blank 2010</a>; <a href="./references#CD007927-bbs2-0011" title="BookmanMA , DarcyKM , Clarke‐PearsonD , BoothbyRA , HorowitzIR . Evaluation of monoclonal humanized anti‐HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2003;21:283‐90. ">Bookman 2003</a>; <a href="./references#CD007927-bbs2-0012" title="CamposS , HamidO , SeidenMV , OzaA , PlanteM , PotkulRK , et al. Multicenter, randomized phase II trial of oral CI‐1033 for previously treated advanced ovarian cancer. Journal of Clinical Oncology2005;23:5597‐604. ">Campos 2005</a>; <a href="./references#CD007927-bbs2-0015" title="ChambersSK , ClouserMC , BakerAF , RoeDJ , CuiH , BrewerMA , et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clinical Cancer Research2010;16(21):5320‐8. University of Arizona, Genentech . Phase II Open‐Label Trial of Erlotinib (Tarceva) and Bevacizumab in Women With Advanced Ovarian Cancer. ClinicalTrials.gov Identifier: NCT00130520. Protocol registered at ClinicalTrials.gov on 12 August 2005. ">Chambers 2010</a>; <a href="./references#CD007927-bbs2-0016" title="CiunciCA , PeriniRF , AvadhaniAN , KangHC , SunW , RedlingerM , et al. Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer2014; Vol. 120, issue 1:77‐85. [DOI: 10.1002/cncr.28294] ">Ciunci 2014</a>; <a href="./references#CD007927-bbs2-0019" title="GarciaAA , SillMW , LankesHA , GodwinAK , MannelRS , ArmstrongDK , et al. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology2012; Vol. 124, issue 3:569‐74. Gynecologic Oncology Group, National Cancer Institute. A Phase II Evaluation of Lapatinib (GW572016) (NCI‐Supplied Agent, NSC #727989) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma. ClinicalTrials.gov Identifier: NCT00113373. Protocol registered at ClinicalTrials.gov on 7 June 2005. ">Garcia 2012</a>; <a href="./references#CD007927-bbs2-0020" title="GordonAN , FinklerN , EdwardsP , GarciaAA , CrozierM , IrwinDH , et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. International Journal of Gynecological Cancer2005;15:785‐92. ">Gordon 2005</a>; <a href="./references#CD007927-bbs2-0021" title="GenentechInc . A Phase II, Open‐label, Multicenter Study to Evaluate the Effect of Tumor‐based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced, Refractory or Recurrent Ovarian Cancer. ClinicalTrials.gov identifier: NCT00058552. Protocol registered at ClinicalTrials.gov on 8 April 2003. GordonMS , MateiD , AghajanianC , MatulonisUA , BrewerM , FlemingGF , et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. Journal of Clinical Oncology2006;24:4324‐32. ">Gordon 2006</a>; <a href="./references#CD007927-bbs2-0022" title="GuastallaJP , AllouacheD , CombeM , WeberB , CretinJ , CureH , et al. HER2 overexpression and amplification in advanced ovarian cancer (AOC): treatment with trustuzumab ‐ a GINECO study. Journal of Clinical Oncology2007;25(18 Suppl):5559. ">Guastalla 2007</a>; <a href="./references#CD007927-bbs2-0023" title="HariprasadR , KumarL , PatnaikR , GuptaA , KumarS . Maintenance therapy in epithelial ovarian cancer: could EGFR‐inhibitor gefitinib be a candidate drug? A pilot study. Journal of Clinical Oncology2006;24(18 Suppl):15046. ">Hariprasad 2006</a>; <a href="./references#CD007927-bbs2-0024" title="HariprasadR , KumarL , KumarS , BhatlaN , ThulkarS , DasP . Advanced epithelial ovarian cancer (EOC): is there a place for maintenance therapy in patients with sub‐optimal debulking?. Journal of Clinical Oncology2009;27(Suppl):abstr e14580. ">Hariprasad 2009</a>; <a href="./references#CD007927-bbs2-0026" title="HirteH , OzaA , HoskinsP , EllardS , GrimshawR , Dubuc‐LissoirJ , et al. Phase II study of OSI‐774 given in combination with carboplatin in patients (pts) with recurrent epithelial ovarian cancer (EOC): NCIC CTG IND.149. European Journal of Cancer2003;1(5 Suppl: ECCO 12 Abstract Book):A‐159, S51. HirteH , OzaA , SwenertonK , EllardSL , GrimshawR , FisherB , et al. A phase II study of erlotinib (OSI‐774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer. Gynecologic Oncology2010;118(3):308‐12. NCIC Clinical Trials Group. A Phase II Study of OSI‐774 (NSC 718781) Given in Combination With Carboplatin in Patients With Recurrent Epithelial Ovarian Cancer. ClinicalTrials.gov identifier: NCT00030446. Protocol registered at ClinicalTrials.gov on 14 February 2002. ">Hirte 2010</a>; <a href="./references#CD007927-bbs2-0028" title="JollyF , WeberB , PautierP , FabbroM , SelleF , KriegerS . Combined topotecan and lapatinib in patients with early recurrent ovarian or peritoneal cancer after first line of platinum based chemotherapy: a French FEDEGYN‐FNCLCC phase II trial. Journal of Clinical Oncology2009;27(15S):Abstract 5555. ">Joly 2009</a>; <a href="./references#CD007927-bbs2-0030" title="ImCloneLLC , Bristol‐MyersSquibb . A Phase II Study of Cetuximab (C225)/Paclitaxel/Carboplatin for the Initial Treatment of Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer. ClinicalTrials.gov Identifier: NCT00063401. Protocol registered at ClinicalTrials.gov on 25 June 2003. KonnerJ , SchilderRJ , DeRosaFA , GerstSR , TewWP , SabbatiniPJ , et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced‐stage ovarian, primary peritoneal or fallopian tube cancer. Gynecologic Oncology2008;110:140‐5. ">Konner 2008</a>; <a href="./references#CD007927-bbs2-0032" title="A Phase II Study of ZD1839 (Iressa) Plus Anastrozole (Arimidex) in Patients With Relapsed Ovarian Cancer. ClinicalTrials.gov Identifier: NCT00181688. Protocol registered at ClinicalTrials.gov on 12 September 2005. KrasnerCN , DebernardoRL , FindleyM , PensonR , MatulonisU , AtkinsonT , et al. Phase II trial of anastrozole in combination with gefitinib in women with asymptomatic mullerian cancer. Journal of Clinical Oncology2005;23:Abstract 5063. ">Krasner 2005</a>; <a href="./references#CD007927-bbs2-0033" title="LheureuxS , KriegerS , WeberB , PautierP , FabbroM , SelleF , et al. Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial. International Journal of Gynecological Cancer2012; Vol. 22, issue 9:1483‐8. ">Lheureux 2012</a>; <a href="./references#CD007927-bbs2-0034" title="JakobsenA , SteffensenKD . Panitumumab and Pegylated Liposomal Doxorubicin for Platinum‐Resistant Epithelial Ovarian Cancer With KRAS Wild‐type (PaLiDo). ClinicalTrials.gov2012. ">NCT00861120</a>; <a href="./references#CD007927-bbs2-0035" title="McCourtC . A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer. ClinicalTrials.gov2011. ">NCT01296035</a>; <a href="./references#CD007927-bbs2-0038" title="PautierP , JolyF , KerbratP , BougnouxP , FumoleauP , PetitT , et al. Phase II study of gefitinib in combination with paclitaxel and carboplatin as second‐line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecologic Oncology2010;116:157‐62. ">Pautier 2010</a>; <a href="./references#CD007927-bbs2-0039" title="PosadasEM , LielMS , KwitkowskiK , MinasianL , GodwinK , HussainMM , et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian tumors. Cancer2007;109(7):1323‐30. ">Posadas 2007</a>; <a href="./references#CD007927-bbs2-0040" title="Ray‐CoquardI , GuastallaJP , AllouacheD , CombeM , WeberB , CretinJ , et al. HER2 overexpression/amplification and trastuzumab treatment in advanced ovarian cancer: a GINECO phase II study. Clinical Ovarian Cancer2008;1(1):54‐9. ">Ray‐Coquard 2008</a>; <a href="./references#CD007927-bbs2-0041" title="Gynecologic Oncology Group, National Cancer Institute. A Phase II Trial of ZD1839 (Iressa) (NSC# 715055) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma. ClinicalTrials.gov Identifier: NCT00023699. Protocol registered at ClinicalTrials.gov on 13 September 2001. SchilderRJ , SillMW , ChenX , DarcyKM , DecesareSL , LewandowskiG , et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of EGFR mutations and immunohistochemical expression: a gynecologic oncology group study. Clinical Cancer Research2005;11(15):5539‐48. ">Schilder 2005</a>; <a href="./references#CD007927-bbs2-0042" title="ImCloneLLC , Bristol‐MyersSquibb . A Phase II Trial of Single‐agent Cetuximab Dose Escalated to Rash in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma. ClinicalTrials.gov Identifier: NCT00082212. Protocol registered at ClinicalTrials.gov on 3 May 2004. SchilderRJ , PathakHB , LokshinAE , HollowayRW , AlvarezRD , AghajanianC , et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecologic Oncology2009;113(1):21‐7. ">Schilder 2009</a>; <a href="./references#CD007927-bbs2-0043" title="Gynecologic Oncology Group. A Phase II Evaluation of Cetuximab (C225, NSC #714692) in Combination With Carboplatin (NSC #241240) in the Treatment of Recurrent Platinum‐Sensitive Ovarian or Primary Peritoneal Cancer. ClinicalTrials.gov Identifier: NCT00086892. Protocol registered at ClinicalTrials.gov on 8 July 2004. SecordAA , BlessingJA , ArmstrongDK , RodgersWH , MinerZ , BarnesMN , et al. A phase II trial of cetuximab and carboplatin in relapsed platinum‐sensitive ovarian cancer and evaluation of epidural growth factor receptor expression: a gynecologic oncology group study. Gynecologic Oncology2008;108(3):493‐4. ">Secord 2008</a>; <a href="./references#CD007927-bbs2-0044" title="EMDSerono . An Open‐Label Phase II Study in Subjects With Recurrent EGFR‐Positive Ovarian Cancer to Investigate the Safety and Efficacy of EMD 72000 Administered as a Single Agent. ClinicalTrials.gov Identifier: NCT00073541. Protocol registered at ClinicalTrials.gov on 24 November 2003. SeidenMV , BurrisHA , MatulonisU , HallJB , ArmstrongDK , SpeyerJ , et al. A phase II trial of EMD72000 (matuzumab), a humanised anti‐EGFR monoclonal antibody, in patients with platinum‐resistant ovarian and primary peritoneal malignancies. Gynecologic Oncology2007;104(3):727‐31. ">Seiden 2007</a>; <a href="./references#CD007927-bbs2-0045" title="SteffensenKD , WaldstrømM , LundB , BergfeldtK , KeldsenN , MarthC , et al. Panitumumab and pegylated liposomal doxorubicin to platinum‐resistant epithelial ovarian cancer with KRAS wild‐type: an ongoing, nonrandomized, multicenter, phase II trial. Journal of Clinical Oncology2010;28(15 Suppl):abstr TPS254. SteffensenKD , WaldstrømM , PallisgardN , LundB , BergfeldtK , WihlJ , et al. Panitumumab and pegylated liposomal doxorubicin in platinum‐resistant epithelial ovarian cancer with KRAS wild‐type: the PaLiDo study, a phase II nonrandomized multicenter study. International Journal of Gynecological Cancer2013;23(1):73‐80. ">Steffensen 2013</a>; <a href="./references#CD007927-bbs2-0048" title="WagnerU , du BoisA , PfistrererJ , HouberJ , LoiblS , LuckHJ , et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum‐taxane based therapy ‐ a phase II trial of the AGO ovarian cancer study group (AGO‐OVAR 2.6). Gynecologic Oncology2007;105(1):132‐7. ">Wagner 2007</a>; <a href="./references#CD007927-bbs2-0049" title="WerohaSJ , ObergAL , ZieglerKL , DakhilmSR , RowlandKM , HartmannLC , et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum‐refractory/resistant ovarian and primary peritoneal carcinoma. Gynecologic Oncology2011; Vol. 122, issue 1:116‐20. ">Weroha 2011</a>). </p> </li> <li> <p>One reference was a protocol for an RCT that compared erlotinib (an EGFR inhibitor) plus bevacizumab (Avastin; a monoclonal antibody that inhibits the vascular endothelial growth factor pathway ‐ another target for novel anticancer drugs) versus bevacizumab alone as first‐line consolidation chemotherapy for women with advanced EOC (<a href="./references#CD007927-bbs2-0014" title="CamposA , AtkinsonT , BerlinA . STAC: a phase II study of carboplatin/paclitaxel/bevacizumab followed by randomization to either bevacizumab alone or erlotinib and bevacizumab in the upfront management of patients with ovarian, fallopian tube or peritoneal cancer [Meeting abstract]. Gynecologic Oncology2011;120(Suppl 1):S79. Abstract 181. Dana‐Farber Cancer Institute. Avastin and Erlotinib as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, and Papillary Serous Mullerian Tumors. ClinicalTrials.gov Identifier: NCT00520013. Protocol registered at ClinicalTrials.gov on 22 August 2007. ">Campos 2011 (NCT00520013)</a>). Although this was an RCT, the comparison is not between an EGFR inhibitor and either standard chemotherapy or no treatment, and thus it did not fulfil our inclusion criteria. </p> </li> <li> <p>One reference was a randomised study of lapatinib monotherapy in a range of cancers; only three randomised participants had EOC, and the study was closed early due to lack of efficacy (<a href="./references#CD007927-bbs2-0018" title="GalskyMD , HoffDD , NeubauerM , AndersonT , FlemingM , NagarwalaY , et al. Target‐specific, histology‐independent, randomized discontinuation study of lapatinib in patients with HER2‐amplified solid tumors. Investigational New Drugs2012; Vol. 30, issue 2:695‐701. ">Galsky 2012</a>). </p> </li> </ul> </p> <p>For further details of all excluded studies, see the <a href="./references#CD007927-sec-0146" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD007927-sec-0085"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD007927-fig-0003">Figure 3</a> for visual representation of risk of bias assessments. </p> <div class="figure" id="CD007927-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007927-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD007927-sec-0086"> <h4 class="title">Allocation</h4> <section id="CD007927-sec-0087"> <h5 class="title">Sequence generation</h5> <p>Four studies did not report the method of generation of the sequence of random numbers used to allocate women to treatment arms (<a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>; <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>; <a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>; <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>). Therefore they were at unclear risk of bias. </p> <p>The other three studies provided details on sequence generation and were at low risk of bias (<a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a>; <a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>; <a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>). </p> </section> <section id="CD007927-sec-0088"> <h5 class="title">Allocation concealment</h5> <p>Three studies were at low risk of bias because researchers explained concealment of allocation and it appeared robust (<a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a>; <a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>; <a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>). Four studies did not mention whether an effort was made to conceal allocation from participants and healthcare professionals involved in the trial (<a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>, <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>; <a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>; <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>). </p> </section> </section> <section id="CD007927-sec-0089"> <h4 class="title">Blinding</h4> <section id="CD007927-sec-0090"> <h5 class="title">Blinding of participants and personnel</h5> <p><a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a> initially blinded participants and healthcare professionals, but subsequently all but one participant discontinued blinded treatment. It is unclear how this may have affected outcomes liable to bias through lack of blinding. <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a> was a double‐blind study but did not describe methods used to ensure blinding. The other five studies were open‐label or included a no treatment control group (<a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>; <a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a>; <a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>; <a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>; <a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>). Therefore they are at high risk of bias for subjective outcomes, such as toxicity and progression‐free survival, but at low risk of bias for overall survival outcomes. </p> </section> <section id="CD007927-sec-0091"> <h5 class="title">Blinding of outcome assessors</h5> <p><a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a> was a double‐blind study but did not describe methods used to ensure blinding. In <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>, it is unclear whether or not outcome assessors were blinded, although this is unlikely to have affected overall survival, which is at low risk of bias. Five studies were open‐label or included a no treatment control group (<a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>; <a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a>; <a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>; <a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>; <a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>). Therefore we deemed these studies to be at high risk of bias for subjective outcomes, such as toxicity and progression‐free survival, but at low risk of bias for overall survival outcomes. </p> </section> </section> <section id="CD007927-sec-0092"> <h4 class="title">Incomplete outcome data</h4> <p>All studies adequately accounted for all women initially included. Quality of life data in <a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a> were limited by low response rates (85% at baseline, ranging from 72% to 51% during the first year and &lt; 50% during the second year), which could suggest high risk of bias, although these data were not available in a form suitable for inclusion in the meta‐analysis. Generally, data on quality of life were poorly reported, making comparison in a meta‐analysis challenging. </p> </section> <section id="CD007927-sec-0093"> <h4 class="title">Selective reporting</h4> <p>Review authors identified five of the included studies before publication and included them as ongoing studies in the previous version of this review (<a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>; <a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a>; <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>; <a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>; <a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>). Data reported were as specified before study completion, although not all outcome data were made available in an analysable form either in the publication or following contact with study authors. Overall, we deemed these studies to be at low or unclear risk of selective reporting bias. </p> </section> <section id="CD007927-sec-0094"> <h4 class="title">Other potential sources of bias</h4> <p>All studies were industry sponsored with links to industry declared by some of the trial authors. However, given that results demonstrated no significant effect, this is unlikely to have had an effect on trial results, especially as the outcomes reported were prespecified. </p> <p>In <a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a>, 33 of 63 women in the control group crossed over to receive vandetanib without chemotherapy on progression of disease. Given that vandetanib appeared to have minimal efficacy, we are unsure how this may have affected overall survival data, although progression‐free survival would not have been affected by cross‐over. </p> </section> </section> <section id="CD007927-sec-0095"> <h3 class="title" id="CD007927-sec-0095">Effects of interventions</h3> <p>See: <a href="./full#CD007927-tbl-0001"><b>Summary of findings for the main comparison</b> EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy</a>; <a href="./full#CD007927-tbl-0002"><b>Summary of findings 2</b> EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer</a>; <a href="./full#CD007927-tbl-0003"><b>Summary of findings 3</b> Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer</a> </p> <section id="CD007927-sec-0096"> <h4 class="title">First‐line treatment</h4> <section id="CD007927-sec-0097"> <h5 class="title">EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment for epithelial ovarian cancer after first‐line chemotherapy </h5> <p>One study examined the role of a tyrosine kinase inhibitor, erlotinib, against EGFR as maintenance/consolidation treatment following response to first‐line chemotherapy (<a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>). </p> <section id="CD007927-sec-0098"> <h6 class="title">Overall survival (risk of death)</h6> <p>See <a href="./references#CD007927-fig-0004" title="">Analysis 1.1</a>; <a href="./full#CD007927-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>There is probably no or little difference in overall survival between erlotinib and observation arms (hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.81 to 1.20; P = 0.90; one study; 835 participants; low‐certainty evidence) (<a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>). Trial authors adjusted both this and progression‐free survival for stratification parameters. Median survival was 50.8 months for participants receiving erlotinib versus 59.1 months for those in the observation arm. There was probably no or little difference in death within 36 months between the two groups (40/100 in control group vs 39/100 in erlotinib group; risk ratio (RR) 0.96, 95% CI 0.82 to 1.14: P = 0.67). </p> </section> <section id="CD007927-sec-0099"> <h6 class="title">Progession‐free survival (risk of disease progression)</h6> <p>See <a href="./references#CD007927-fig-0005" title="">Analysis 1.2</a>; <a href="./full#CD007927-tbl-0001">summary of findings Table for the main comparison</a> </p> <p>This study was powered for a primary outcome of progression‐free survival, and there may be no or little difference between treatment groups (HR 1.05, 95% CI 0.90 to 1.23; one study; 835 participants; P = 0.53; very low‐certainty evidence) with median progression‐free survival of 12.7 months in the erlotinib group versus 12.4 months in the observation arm. Two participants died before clinical progression was observed and are included in these figures (clarification obtained from study authors). There may be no or little difference in risk of progression within 12 months between groups (50 episodes of progression in the observation arm vs 48 in the erlotinib arm per 100 women; RR 0.96, 95% CI 0.84 to 1.11; P = 0.61). </p> </section> <section id="CD007927-sec-0100"> <h6 class="title">Quality of life and adverse effects</h6> <p>Researchers recorded quality of life data, but reporting was incomplete and was limited by low compliance (85% at baseline, 72% to 51% during the first year, and less than 50% during the second year; one study; 835 participants; very low‐certainty evidence). Study authors stated that there was a significant difference in global health/quality of life scores during the first year (P = 0.010) and "QLO‐C30 found statistically significant differences at the 5% level in symptom levels for diarrhoea [sic], loss of appetite, nausea/vomiting, and fatigue, with worse symptom scores for the erlotinib arm", but further data were not made available, despite requests to the study author; therefore, we could not include these in the meta‐analysis, nor could we include toxicity data, because only data for the erlotinib arm were published and comparison group data have not been provided, despite communication with study authors. In terms of erlotinib toxicity, the main side effects were rash (grade 1 to 2, 67%; grade 3 to 4, 12.8%) and diarrhoea (grade 1 to 2, 55.2%; grade 3 to 4, 4.8%) (<a href="./full#CD007927-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> </section> <section id="CD007927-sec-0101"> <h4 class="title">Treatment for recurrent disease</h4> <section id="CD007927-sec-0102"> <h5 class="title">EGFR TKI plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer </h5> <p>One study, which included 129 participants, examined the addition of vandetanib to docetaxel chemotherapy for treatment of recurrent disease (<a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a>). The primary outcome was progression‐free survival, and the study was powered to detect an increase in median progression‐free survival of two months. Overall survival and adverse effects were secondary outcomes; researchers reported and graded adverse effects by National Cancer Institute Common Toxicity Criteria version 2.0 (<a href="./references#CD007927-bbs2-0059" title="Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf2017. ">CTEP 2017</a>). Post hoc analysis revealed no subgroups that benefited from erlotinib. It was noted that a positive fluorescence in situ hybridisation (FISH) score for EGFR expression was a marker of poor prognosis in both arms (overall survival 46.1 months vs negative FISH EGFR score 67.0 months; HR, 1.56, 95% CI 1.01 to 2.40; P = .044). </p> <section id="CD007927-sec-0103"> <h6 class="title">Overall survival</h6> <p>See <a href="./references#CD007927-fig-0006" title="">Analysis 2.1</a>; <a href="./full#CD007927-tbl-0002">summary of findings Table 2</a>. </p> <p>There is probably no or little difference in overall survival between docetaxel plus or minus vandetanib (HR 1.25, 95% CI 0.80 to 1.95; one study; 125 participants; low‐certainty evidence), although the study was not powered to find a difference in overall survival. Another confounder was that 33 of 63 women in the control group crossed over to receive vandetanib without chemotherapy on progression. However, lack of effect on progression‐free survival suggests that these data are valid, as the addition of vandetanib appeared to have minimal efficacy. </p> </section> <section id="CD007927-sec-0104"> <h6 class="title">Progression‐free survival</h6> <p>See <a href="./references#CD007927-fig-0007" title="">Analysis 2.2</a>; <a href="./full#CD007927-tbl-0002">summary of findings Table 2</a>. </p> <p>There may be little or no difference in progression‐free survival (HR 0.99, 95% CI 0.69 to 1.42; P = 0.49; one study; 125 participants; very low‐certainty evidence). Median progression‐free survival time was three months in the docetaxel/vandetanib group versus 3.5 months in the docetaxel‐only control group. </p> </section> <section id="CD007927-sec-0105"> <h6 class="title">Toxicity</h6> <p>See <a href="./references#CD007927-fig-0008" title="">Analysis 2.3</a>; <a href="./references#CD007927-fig-0027" title="">Analysis 2.22</a>; <a href="./full#CD007927-tbl-0002">summary of findings Table 2</a>. </p> <p>Rash was the main side effect in the vandetanib group, with six (10%) women experiencing grade 3 to 4 rash compared to 0 (0%) in the control group, although this result had very wide confidence intervals due to the small number of events (RR 13.63, 95% CI 0.78 to 236.87; I² = 0%; one study; 125 participants; very low‐certainty evidence). For rash of any grade, there were 11 cases (18%) in the control group versus 30 (49%) in the docetaxel/vandetanib group. </p> </section> </section> <section id="CD007927-sec-0106"> <h5 class="title">Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer </h5> <p>We found three studies evaluating the anti‐HER‐2 monoclonal antibody, pertuzumab (<a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>; <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a> ;<a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>); one study evaluating panitumumab, an anti‐EGFR antibody (<a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>); and one study evaluating an anti‐HER‐3 antibody (seribantumab) (<a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>), all in the context of relapsed/recurrent disease. </p> <p><a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a> was an open‐label RCT of 149 women that compared six cycles of chemotherapy (carboplatin and either paclitaxel (Taxol) or gemcitabine) with or without pertuzumab in a platinum‐sensitive setting. </p> <p>Three studies evaluated anti‐EGFR antibodies in platinum‐refractory or ‐resistant disease. <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>, which included 130 women with platinum‐resistant disease, was a double‐blinded placebo‐controlled RCT that reported data on gemcitabine plus pertuzumab versus gemcitabine plus placebo. <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a> included 156 women with platinum‐resistant or ‐refractory disease who received chemotherapy plus either pertuzumab or placebo. <a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a> included 223 women with platinum‐refractory or ‐resistant disease. </p> <p><a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a> was also conducted in a platinum‐sensitive setting and recruited 103 women but analysed 96 with <i>KRAS</i> (gene) wild‐type, platinum‐sensitive recurrent EOC. Women were treated with carboplatin plus gemcitabine or pegylated doxorubicin plus or minus panitumumab ‐ a fully human antibody to EGFR. Researchers provided data only in abstract form, and we were not able to further evaluate them as part of the meta‐analysis. We have presented a narrative description of study results (see <a href="./references#CD007927-sec-0145" title="">Characteristics of included studies</a>). </p> <section id="CD007927-sec-0107"> <h6 class="title">Overall survival</h6> <p>See <a href="./references#CD007927-fig-0028" title="">Analysis 3.1</a>; <a href="./full#CD007927-tbl-0003">summary of findings Table 3</a> </p> <p>There may be no or little difference in overall survival between women who received an anti‐EGFR antibody and those given placebo/chemotherapy alone (HR 0.93, 95% CI 0.74 to 1.18; four studies; 658 participants; I² = 0%) (the percentage of variability in effect estimates that is due to heterogeneity rather than to sampling error (chance) is not important); moderate‐certainty evidence; <a href="./references#CD007927-fig-0028" title="">Analysis 3.1</a>). There was little or no difference in effect depending on whether the study was conducted in a platinum‐sensitive (HR 1.02, 95% CI 0.63 to 1.67; one study; 149 participants; I² = not applicable) or a platinum‐resistant/refractory setting (HR 0.91, 95% CI 0.70 to 1.18; I² = 0% (the percentage of variability in effect estimates that is due to heterogeneity rather than to sampling error (chance) is not important); three studies; 509 participants; <a href="./references#CD007927-fig-0028" title="">Analysis 3.1</a>). </p> <p><a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a> mentioned no adjustment, although randomisation was stratified by treatment‐free interval (TFI; six to 12 months vs more than 12 months), measurable versus non‐measurable disease, chemotherapy regimen (carboplatin–paclitaxel vs carboplatin–gemcitabine), and territory (Eastern Europe vs Western Europe and Canada). Both studies were exploratory studies and were not powered to detect a difference in overall survival. The median overall survival, after two years of follow‐up, was 28.2 weeks in the pertuzumab group but was not reached in the control group. </p> <p>In <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>, overall survival was 10.2 months (95% CI 6.7 to 15.2 months) in the pertuzumab group versus 8.4 months (95% CI 6.1 to 12.0 months) in the placebo group. </p> <p><a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a> reported 91 (70%) deaths and adjusted estimates of survival outcomes for important prognostic factors, including ECOG score and measurable disease. The median overall survival was 13 months and 13.1 months in the intervention and placebo groups, respectively. </p> <p>In <a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>, median overall survival for S + P was 13.7 months versus 10.12 months for paclitaxel alone (HR 0.99, 95% CI 0.62 to 1.584; P = 0.972). </p> <p><a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a> stated in its conference proceedings abstract that data on overall survival were not yet evaluable and provided no further data. </p> </section> <section id="CD007927-sec-0108"> <h6 class="title">Progression‐free survival</h6> <p>See <a href="./references#CD007927-fig-0029" title="">Analysis 3.2</a>; <a href="./full#CD007927-tbl-0003">summary of findings Table 3</a>. </p> <p>There may be no or little difference in risk of disease progression among women who received an anti‐EGFR antibody (HR 0.90, 95% CI 0.70 to 1.16; four studies; 658 participants; low‐certainty evidence; <a href="./references#CD007927-fig-0029" title="">Analysis 3.2</a>). There may or may not be a difference in effect, depending on whether this study was conducted in a platinum‐sensitive (HR 1.17, 95% CI 0.81 to 1.70; one study; 149 participants; <a href="./references#CD007927-fig-0029" title="">Analysis 3.2</a>) or a platinum‐resistant/refractory setting (HR 0.82, 95% CI 0.63 to 1.09; three studies; 509 participants; <a href="./references#CD007927-fig-0029" title="">Analysis 3.2</a>). </p> <p><a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a> stated: "progression‐free survival in the intention‐to‐treat population (N = 96) was 9.5 versus 10.7 months (95% CI [of] 8.5 to 11.6 months versus 8.5 to 13.1 months) for the experimental versus [the] standard arm; P = 0.45". Researchers did not state how many participants were included in each group, and review authors were unable to extract data for inclusion in the meta‐analysis. Study authors provided an HR of 0.829 but no CI. Therefore, it was not possible to include these data in the meta‐analysis. </p> <p>In <a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>, the median progression‐free survival in platinum‐sensitive relapsed disease was 34.1 months in the chemotherapy/pertuzumab group versus 40 months in the chemotherapy alone group. </p> <p><a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a> reported 103 (79%) cases of disease progression and median progression‐free survival of 2.9 months and 2.6 months in intervention and placebo groups, respectively. </p> <p>In <a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>, the median progression‐free survival for seribantumab plus paclitaxel was 3.75 months versus 3.68 months for paclitaxel alone (HR 1.027, 95% CI 0.741 to1.425; P = 0.864). </p> </section> <section id="CD007927-sec-0109"> <h6 class="title">Grade 3 or 4 adverse events</h6> <p>See <a href="./references#CD007927-fig-0030" title="">Analysis 3.3</a> through <a href="./references#CD007927-fig-0045" title="">Analysis 3.18</a>; <a href="./full#CD007927-tbl-0003">summary of findings Table 3</a>. </p> <p>Combining pertuzumab and seribantumab may or may not have an effect on the incidence of severe diarrhoea (RR 2.87, 95% CI 0.59 to 13.89; I² = 59%; four studies; 652 participants; very low‐certainty evidence; <a href="./references#CD007927-fig-0035" title="">Analysis 3.8</a>). However, data show heterogeneity of effect between the different antibodies, and so we analysed these separately. Women who received the anti‐EGFR antibody pertuzumab probably reported an increase in diarrhoea, with a six‐fold increased risk of severe diarrhoea (<a href="./references#CD007927-fig-0035" title="">Analysis 3.8</a>.1; three studies; 432 participants; RR 6.37, 95% CI 1.89 to 21.45; I² = 0%; low‐certainty evidence). Seribantumab may or may not have an effect on diarrhoea (<a href="./references#CD007927-fig-0035" title="">Analysis 3.8</a>.2; one study; 220 participants; RR 0.38, 95% CI 0.07 to 2.23; I² = 0%; very low‐certainty evidence). </p> <p>Due to the small numbers of participants included in the studies and low numbers of grade 3 and 4 events in either arm, confidence intervals for all grade 3 and 4 toxicities were extremely wide, and there is low‐certainty about whether pertuzumab or seribantumab had an effect on other toxicities. </p> <p><a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a> stated: "The most common treatment related grade 3 plus toxicities included hematologic toxicity (54%), skin reactions (18%), and gastrointestinal events (16%)". It is unclear whether this was so in the panitumumab group, but it is not possible to include these data in the meta‐analysis, as numbers in each group are not stated and there appear to be no control group data. We have contacted trial authors for clarification, but they have not yet provided data. </p> </section> <section id="CD007927-sec-0110"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a> presented quality of life data (Hilpert 2016, in <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>). Overall abdominal and gastrointestinal quality of life QLQ‐OV28 (EORTC module for ovarian cancer) scores showed no differences between groups (profile difference 3.9, 95% CI ‐3.3 to 11.2; P value not given in abstract). However, diarrhoeal symptoms were worse with pertuzumab, with a quality of life score profile difference of 21.2 (95% CI 10.1 to 32.3; P = 0.0003). <a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a> reported "no significant changes from baseline", although study authors provided no specific data. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007927-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007927-sec-0111">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007927-sec-0181">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007927-sec-0111"></div> <section id="CD007927-sec-0112"> <h3 class="title" id="CD007927-sec-0112">Summary of main results</h3> <section id="CD007927-sec-0113"> <h4 class="title">First‐line treatment</h4> <p>We included one study that treated women after completion of first‐line chemotherapy for epithelial ovarian cancer (EOC) (<a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>). All women had demonstrated a response to conventional first‐line platinum‐based chemotherapy and to erlotinib, a tyrosine kinase inhibitor, which was given as maintenance treatment until demonstration of disease progression. There was probably little or no difference in either overall or progression‐free survival when erlotinib was added as maintenance following conventional first‐line chemotherapy. Researchers did not report quality of life data in a format amenable to inclusion in a meta‐analysis, but they reported a significant increase in symptom levels in the erlotinib group, especially for diarrhoea, loss of appetite, nausea and vomiting, and fatigue, compared to the non‐treatment arm, although lack of blinding and placebo reduces the certainty of this finding, which is subjective and prone to bias without a blinded placebo control group. Development of a rash was more common in the treatment group (<a href="./full#CD007927-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD007927-sec-0114"> <h4 class="title">Treatment for recurrent disease</h4> <p>We included six studies in the context of recurrent EOC ‐ one comparing vandetanib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (<a href="./references#CD007927-bbs2-0002" title="ColemanRL , MoonJ , SoodA , BranhamD , DelmoreJE , BonebrakeAJ , et al. Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D‐V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. European Journal of Cancer2014; Vol. 50, issue 9:1638‐48. Southwest Oncology Group, National Cancer Institute. Docetaxel with or without vandetanib in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00872989). Protocol registered at ClinicalTrials.gov on 31 March 2009. ">Coleman 2014</a>); three comparing pertuzumab, an anti‐EGFR antibody (<a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>; <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>; <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>); one comparing panitumumab, the anti‐EGFR antibody (<a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>); and one comparing seribantumab, the anti‐EGFR antibody (<a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>). None of these studies demonstrated benefit in terms of overall or progression‐free survival. Diarrhoea was probably more common in the pertuzumab‐treated group, but other than that, the confidence intervals for adverse events were very wide and our certainty of findings was low (downgraded due to high risk of bias, lack of or unclear blinding, and imprecision) (<a href="./full#CD007927-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD007927-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> <section id="CD007927-sec-0115"> <h3 class="title" id="CD007927-sec-0115">Overall completeness and applicability of evidence</h3> <p>With the exception of <a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>, all of the included studies were small randomised phase II studies, and escalation to phase III is not planned or was abandoned due to lack of demonstrated efficacy in these studies. Studies were largely powered for progression‐free survival outcomes, rather than overall survival. </p> <p>Although we specified quality of life as an outcome of interest, none of the included studies fully reported this outcome in a form that could be included in the meta‐analysis. Quality of life data collection was poor, with low compliance rates in <a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>, perhaps reflecting the burden of completing questionnaires for the women involved in the studies. These data were also at high risk of bias in <a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a> due to lack of blinding and placebo control. Quality of life after treatment for cancer, especially in a palliative setting (as is the case for advanced and recurrent EOC), is an extremely important outcome, as treatment‐related morbidity very often degrades the quality of the time patients may gain as a result of treatment. </p> </section> <section id="CD007927-sec-0116"> <h3 class="title" id="CD007927-sec-0116">Quality of the evidence</h3> <p>The certainty of the evidence overall was low to very low (downgraded due to small numbers of participants and events, resulting in imprecision and lack of/unclear blinding) (<a href="./references#CD007927-bbs2-0069" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐4. ">GRADE Working Group</a>), although evidence for overall survival outcomes showed moderate to low‐certainty because this outcome was unlikely to have been biased by lack of blinding in some studies. </p> <section id="CD007927-sec-0117"> <h4 class="title">EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy </h4> <p>Evidence for overall survival results and death from any cause by 36 months is of low‐certainty, and we downgraded it by one level for imprecision (confidence intervals that cross zero and a single study) and by a further level for inability to assess consistency, because only one study was included. Lack of placebo or blinding is unlikely to have affected this outcome. We judged evidence for progression‐free survival and progression by 12 months to be of very low‐certainty. We downgraded certainty by three levels because of inability to test for inconsistency, imprecision (confidence intervals that cross zero and a single study), and risk of bias (unblinded). We judged quality of life data to be of very low‐certainty and downgraded certainty by at least three levels due to the possibility of selective reporting bias (incompletely reported predefined outcome, so possibility of selective outcome reporting); inability to test for inconsistency because a single study was included; risk of bias (unblinded) as no data are available by which to analyse effect and outcomes are highly likely to be affected by lack of blinding; and imprecision (<a href="./full#CD007927-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD007927-sec-0118"> <h4 class="title">EGFR TKI plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer </h4> <p>We judged evidence for overall survival results to be of very low‐certainty, and we downgraded it by three levels due to imprecision (one small study, wide confidence intervals that cross zero, and too few events for adequate power) and inability to test for inconsistency, as only one study was included in this analysis. Lack of placebo or blinding is unlikely to have affected this outcome. We judged evidence for progression‐free survival and adverse effects to be of very low‐certainty. We downgraded certainty by three levels due to imprecision and inability to test for inconsistency, and by another level for risk of bias (unblinded). Data on quality of life were not available (<a href="./full#CD007927-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD007927-sec-0119"> <h4 class="title">Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer </h4> <p>Evidence for overall survival results was limited to pertuzumab, and we judged it to be of moderate certainty; we downgraded it by one level due to imprecision (wide confidence intervals that cross zero and too few events for adequate power). Lack of placebo or blinding is unlikely to have affected this outcome. We judged evidence for progression‐free survival and adverse effects to be of low to very low‐certainty. We downgraded certainty by two levels due to imprecision, by another level for risk of bias (unblinded), and by a further level when we noted inconsistency in outcomes between different EGFR antibodies. Data on quality of life were not available for analysis (<a href="./full#CD007927-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> <section id="CD007927-sec-0120"> <h3 class="title" id="CD007927-sec-0120">Potential biases in the review process</h3> <p>We performed a comprehensive search, including a thorough search of the grey literature, and two or more review authors sifted all studies and extracted data independently. We restricted the included studies to randomised controlled trials (RCTs), as they provide the strongest level of evidence. Several studies were open‐label or included an observation control arm, which presents major potential for bias. This is likely to primarily affect less robust outcome measures, such as toxicity and quality of life, for which side effects would be more likely to be reported by participants taking an active drug than by those undergoing observation only. </p> <p>The greatest threat to the validity of the review is likely to be the possibility of publication bias (i.e. studies that did not find anti‐EGFR treatment for EOC to have been effective may not have been published). We were unable to assess this possibility formally, although three of the studies included in this review update were identified before data were available, and none of the included studies demonstrated a positive effect. </p> </section> <section id="CD007927-sec-0121"> <h3 class="title" id="CD007927-sec-0121">Agreements and disagreements with other studies or reviews</h3> <p>Several review articles have noted the disappointing results of anti‐EGFR agents in clinical trials compared to promising results in preclinical studies. </p> <p><a href="./references#CD007927-bbs2-0092" title="WilkenJA , BadriT , CrossS , RajiR , SantinAD , BranscumJ , et al. EGFR/HER‐targeted therapeutics in ovarian cancer. Future Medicinal Chemistry2012; Vol. 4, issue 4:447‐69. ">Wilken 2012</a> reviewed the results of clinical trials of anti‐EGFR treatment, including non‐randomised phase I and II studies (this group included trials by <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a> and <a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>) and noted that trial results did not demonstrate improvement compared to conventional treatment. The phase I toII trials reported low response rates for many anti‐EGFR agents, including cetuximab (anti‐EGFR antibody); trastuzumab (anti‐human epidermal growth factor receptor (HER)‐2 antibody); matuzumab (anti‐EGFR antibody); leflunomide (platelet‐derived growth factor receptor (PDGFR)/fibroblast growth factor receptor (FGFR)/EGFR tyrosine kinase inhibitor (TKI)); vandetanib (EGFR/VEGFR‐2/transmembrane receptor tyrosine kinase (RET) TKI); canertinib (EGFR/HER‐2/HER‐4/EGFRvIII TKI); lapatinib (EGFR/HER‐2 TKI); erlotinib (EGFR TKI); and gefitinib (EGFR TKI). Review authors commented that "a stark contrast exists between the <i>in vitro</i> evaluation of HER‐targeted therapeutics and predicted clinical outcomes in women with EOC treated with HER‐targeted therapeutics", and discussed how preclinical assessment of cell lines in vivo did not correlate well with the clinical outcomes observed, and that better preclinical models were required. </p> <p><a href="./references#CD007927-bbs2-0089" title="TeplinskyE , MuggiaF . EGFR and HER2: is there a role in ovarian cancer?. Translational Cancer Research2015;4(1):107‐17. ">Teplinsky 2015</a> reviewed clinical studies, including <a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>, <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>, and <a href="./references#CD007927-bbs2-0007" title="European Organization for Research and Treatment of Cancer. Erlotinib or observation in treating patients who have undergone first‐line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer (MRC OV07). Protocol registered at ClinicalTrials.gov on 7 December2005. VergoteIB , JimenoA , JolyF , KatsarosD , CoensC , DespierreE , et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first‐line platin‐based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer‐Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology2014; Vol. 32, issue 4:320‐6. ">Vergote 2014</a>, and concluded that due to "discouraging results...at this point, there seems to be little role for anti‐EGFR or HER‐2 directed therapies in EOC outside of clinical trials". </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007927-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="(A) The EGFR is a transmembrane protein. (B) Following binding to its ligand, EGF, the EGFR is stimulated and develops tyrosine kinase activity. (C) Tyrosine kinase activity sets off a sequence of downstream events that lead to stimulation of cell growth. (D) EGFR activity can be blocked by antibodies that prevent EGF binding to the receptor or by use of chemicals that inhibit tyrosine kinase enzyme activity." data-id="CD007927-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>(A) The EGFR is a transmembrane protein. (B) Following binding to its ligand, EGF, the EGFR is stimulated and develops tyrosine kinase activity. (C) Tyrosine kinase activity sets off a sequence of downstream events that lead to stimulation of cell growth. (D) EGFR activity can be blocked by antibodies that prevent EGF binding to the receptor or by use of chemicals that inhibit tyrosine kinase enzyme activity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007927-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007927-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy, Outcome 1 Overall survival." data-id="CD007927-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy, Outcome 2 Progression‐free survival." data-id="CD007927-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy, Outcome 2 Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 1 Overall survival." data-id="CD007927-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 2 Progression‐free survival." data-id="CD007927-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 2 Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 3 Toxicity: grade 3 or 4 neutropaenia." data-id="CD007927-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 3 Toxicity: grade 3 or 4 neutropaenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 4 Toxicity: grade 3 or 4 febrile neutropaenia." data-id="CD007927-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 4 Toxicity: grade 3 or 4 febrile neutropaenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 5 Toxicity: grade 3 or 4 leucopaenia." data-id="CD007927-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 5 Toxicity: grade 3 or 4 leucopaenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 6 Toxicity: grade 3 or 4 leucocytosis." data-id="CD007927-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 6 Toxicity: grade 3 or 4 leucocytosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 7 Toxicity: grade 3 or 4 thrombocytopaenia." data-id="CD007927-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 7 Toxicity: grade 3 or 4 thrombocytopaenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 8 Toxicity: grade 3 or 4 anaemia." data-id="CD007927-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 8 Toxicity: grade 3 or 4 anaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 9 Toxicity: grade 3 or 4 nausea ± vomiting." data-id="CD007927-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 9 Toxicity: grade 3 or 4 nausea ± vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 10 Toxicity: grade 3 or 4 constipation." data-id="CD007927-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 10 Toxicity: grade 3 or 4 constipation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 11 Toxicity: grade 3 or 4 rash." data-id="CD007927-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 11 Toxicity: grade 3 or 4 rash. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 12 Toxicity: grade 3 or 4 allergic reaction/drug hypersensitivity." data-id="CD007927-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 12 Toxicity: grade 3 or 4 allergic reaction/drug hypersensitivity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 13 Toxicity: grade 3 or 4 skin toxicity (other)." data-id="CD007927-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 13 Toxicity: grade 3 or 4 skin toxicity (other). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 14 Toxicity: grade 3 or 4 fatigue." data-id="CD007927-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 14 Toxicity: grade 3 or 4 fatigue. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 15 Toxicity: cardiac toxicity (any grade)." data-id="CD007927-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 15 Toxicity: cardiac toxicity (any grade). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 16 Toxicity: grade 3 or 4 hypokalaemia." data-id="CD007927-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 16 Toxicity: grade 3 or 4 hypokalaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 17 Toxicity: grade 3 or 4 hypocalcaemia." data-id="CD007927-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 17 Toxicity: grade 3 or 4 hypocalcaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 18 Toxicity: grade 3 or 4 hypomagnesaemia." data-id="CD007927-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 18 Toxicity: grade 3 or 4 hypomagnesaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 19 Toxicity: grade 3 or 4 anorexia." data-id="CD007927-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 19 Toxicity: grade 3 or 4 anorexia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 20 Toxicity: grade 3 or 4 neuropathy." data-id="CD007927-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 20 Toxicity: grade 3 or 4 neuropathy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 21 Toxicity: grade 3 or 4 oedema." data-id="CD007927-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 21 Toxicity: grade 3 or 4 oedema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 22 Toxicity: treatment‐related secondary malignancy." data-id="CD007927-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 22 Toxicity: treatment‐related secondary malignancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 1 Overall survival." data-id="CD007927-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 2 Progression‐free survival." data-id="CD007927-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 2 Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 3 Toxicity: grade 3 or 4 neutropaenia." data-id="CD007927-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 3 Toxicity: grade 3 or 4 neutropaenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 4 Toxicity: grade 3 or 4 febrile neutropaenia." data-id="CD007927-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 4 Toxicity: grade 3 or 4 febrile neutropaenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 5 Toxicity: grade 3 or 4 leucopaenia." data-id="CD007927-fig-0032" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 5 Toxicity: grade 3 or 4 leucopaenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 6 Toxicity: grade 3 or 4 thrombocytopaenia." data-id="CD007927-fig-0033" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 6 Toxicity: grade 3 or 4 thrombocytopaenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 7 Toxicity: grade 3 or 4 anaemia." data-id="CD007927-fig-0034" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 7 Toxicity: grade 3 or 4 anaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 8 Toxicity: grade 3 or 4 diarrhoea." data-id="CD007927-fig-0035" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 8 Toxicity: grade 3 or 4 diarrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 9 Toxicity: grade 3 or 4 nausea ± vomiting." data-id="CD007927-fig-0036" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 9 Toxicity: grade 3 or 4 nausea ± vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 10 Toxicity: grade 3 or 4 dyspepsia." data-id="CD007927-fig-0037" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 10 Toxicity: grade 3 or 4 dyspepsia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 11 Toxicity: grade 3 or 4 abdominal pain." data-id="CD007927-fig-0038" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 11 Toxicity: grade 3 or 4 abdominal pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 12 Toxicity: grade 3 or 4 rash." data-id="CD007927-fig-0039" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 12 Toxicity: grade 3 or 4 rash. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 13 Toxicity: grade 3 or 4 allergic reaction/drug hypersensitivity." data-id="CD007927-fig-0040" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 13 Toxicity: grade 3 or 4 allergic reaction/drug hypersensitivity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 14 Toxicity: grade 3 or 4 skin toxicity (other)." data-id="CD007927-fig-0041" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 14 Toxicity: grade 3 or 4 skin toxicity (other). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 15 Toxicity: grade 3 or 4 fatigue." data-id="CD007927-fig-0042" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 15 Toxicity: grade 3 or 4 fatigue. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 16 Toxicity: cardiac toxicity (any grade)." data-id="CD007927-fig-0043" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 16 Toxicity: cardiac toxicity (any grade). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 17 Toxicity: grade 3 or 4 hypokalaemia." data-id="CD007927-fig-0044" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 17 Toxicity: grade 3 or 4 hypokalaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007927-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/urn:x-wiley:14651858:media:CD007927:CD007927-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_t/tCD007927-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 18 Toxicity: grade 3 or 4 back pain." data-id="CD007927-fig-0045" src="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer, Outcome 18 Toxicity: grade 3 or 4 back pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/media/CDSR/CD007927/image_n/nCD007927-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007927-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy<br/> <b>Setting:</b> hospital outpatient treatment of women with ovarian/fallopian tube/primary peritoneal cancer after response to first‐line chemotherapy<br/> <b>Intervention:</b> EGFR tyrosine kinase inhibitor (TKI)<br/> <b>Comparison:</b> observation alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with observation alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with EGFR tyrosine kinase inhibitor (TKI)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median 50.8 months in the EGFR TKI group vs 59.1 months in the observation arm</p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.99<br/> (0.81 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>835<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome unlikely to be affected by blinding. due to the way HRs are calculated, the assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median PFS of 12.7 months in the EGFR TKI group vs 12.4 months in the observation arm </p> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.05<br/> (0.90 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>835<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>due to the way HRs are calculated, the assumed and corresponding risks were not estimated.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with EORTC QLQ‐C30 and OV28 (Ovarian Cancer Module) questionnaires </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>"Global health/QOL scores showed a significant overall difference between the two treatment arms during the first year (P 0.0102) in favour of the observation arm. In addition, the QLQ‐C30 found statistically significant differences at the 5% level in symptom levels for diarrhoea, loss of appetite, nausea/vomiting, and fatigue, with worse symptom scores for the erlotinib arm. None of the scales, however,reported differences of 10 points except for the diarrhoea [sic] scale in which differences of more than 20 points were observed at most assessments during the first year. Sensitivity analyses by means of imputation revealed similar results". </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>835<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysable data were not provided in the published paper or after communication with the study author, and so we were unable to analyse or exclude selective reporting bias. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; EGFR: epidermal growth factor receptor; HR: hazard ratio; RR: risk ratio; OR: odds ratio; PFS: progression‐free survival; QOL: quality of life; QLQ‐C30: Quality of Life Questionnaire C30; RCT: randomised controlled trial; TKI: tyrosine kinase inhibitor. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><a href="./references#CD007927-bbs2-0069" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐4. ">GRADE Working Group</a> grades of evidence<br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels for imprecision (confidence intervals that cross zero and single study) and inability to assess inconsistency, as results were based on a single study.<br/> <sup>b</sup>Downgraded by three levels due to risk of bias (unblinded study); imprecision (confidence intervals that cross zero and single study); and inability to assess inconsistency, as results were based on a single study.<br/> <sup>c</sup>Downgraded by three levels due to the possibility of selective reporting bias (incompletely reported predefined outcome, so possibility of selective outcome reporting); imprecision; and risk of bias (unblinded), as no data were available to analyse effect and outcome was highly likely to be affected by lack of blinding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007927-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> treatment of relapsed epithelial ovarian cancer<br/> <b>Setting:</b> hospital outpatient treatment of women with relapsed ovarian/fallopian tube/primary peritoneal cancer<br/> <b>Intervention:</b> EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy<br/> <b>Comparison:</b> chemotherapy alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with chemotherapy alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median OS for chemotherapy alone was 18 months compared to 14 months in the chemotherapy plus EGFR TKI arm. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.25<br/> (0.80 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome unlikely to be affected by blinding. due to the way HRs are calculated, the assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median PFS for chemotherapy only was 3.5 months compared to a median PFS of 3.0 months in the chemotherapy plus EGFR TKI arm. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.99<br/> (0.69 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>due to the way HRs are calculated, the assumed and corresponding risks were not estimated.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 rash<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or CommonTerminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 13.63<br/> (0.78 to 236.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100<br/> (1 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 nausea ± vomiting<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/> (0.16 to 2.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<br/> (1 to 20) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 fatigue<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.28 to 2.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 100<br/> (3 to 26) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: cardiac toxicity (any grade)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.24<br/> (0.26 to 107.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/> (4 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life: not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No QoL data included in the publication</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; CTCAE: Common Terminology Criteria for Adverse Events; EGFR: epidermal growth factor receptor; HR: hazard ratio; PFS: progression‐free survival; QoL: quality of life; RCT: randomised controlled trial; RR: risk ratio; TKI: tyrosine kinase inhibitor </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><a href="./references#CD007927-bbs2-0069" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐4. ">GRADE Working Group</a> grades of evidence<br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Outcome unlikely to be affected by lack of blinding.<br/> <sup>b</sup>Downgraded by two levels due to imprecision (one small study, wide confidence intervals that cross zero, and too few events for adequate power).<br/> <sup>c</sup>Downgraded by three levels due to risk of bias (blinding absent or unclear); imprecision; and inability to assess inconsistency (one small study, wide confidence intervals that cross zero, and too few events for adequate power). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007927-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> treatment of relapsed epithelial ovarian cancer<br/> <b>Setting:</b> hospital outpatient treatment of women with ovarian/fallopian tube/primary peritoneal cancer after response to first‐line chemotherapy<br/> <b>Intervention:</b> anti‐EGFR antibody plus chemotherapy<br/> <b>Comparison:</b> chemotherapy alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative<br/> effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with chemotherapy alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐EGFR antibody plus chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median OS by study in intervention and placebo groups, respectively</p> <p><a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>: "overall survival are not yet evaluable" </p> <p><a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>: 28.2 months vs median overall survival not reached </p> <p><a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>: median OS 10.2 months vs 8.4 months </p> <p><a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>: median OS 13.7 months vs 10.12 months </p> <p><a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>: median OS 13 months and 13.1 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.93<br/> (0.74 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>658<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome unlikely to be affected by blinding. due to the way HRs are calculated, the assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median progression‐free survival (PFS) by study in intervention and placebo groups, respectively </p> <p><a href="./references#CD007927-bbs2-0001" title="ChekerovR , KlareP , KrabischP , PotenbergJ , HeinrichG , MuellerL , et al. Panitumumab in platinum‐sensitive epithelial ovarian cancer patients with KRAS wild‐type: the PROVE‐study, a phase II randomized multicenter study of the North‐Eastern German Society of Gynaecologic Oncology. Journal of Clinical Oncology2017;35(15):5558. WiSP Wissenschaftlicher Service PharmaGmbH . PROVE: A Randomized Phase II Trial of Standard Carboplatin‐based Chemotherapy With or Without Panitumumab in Platinum‐sensitive Recurrent Ovarian Cancer. ClinicalTrials.govMay 2011. ">Chekerov 2017</a>: median PFS 9.5 months vs 10.7 months </p> <p><a href="./references#CD007927-bbs2-0003" title="KayeSB , PooleCJ , BidzinskiM , GianniL , GorbunovaV , NovikovaE , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology2008;26(Suppl):Abstract 5520. KayeSB , PooleCJ , Danska‐BidzinskaA , GianniL , DelConteG , GorbunovaV , et al. A randomized phase II study evaluating the combination of carboplatin‐based chemotherapy with pertuzumab versus carboplatin‐based therapy alone in patients with relapsed, platinum‐sensitive ovarian cancer. Annals of Oncology2013;14(1):145‐52. ">Kaye 2013</a>: median PFS 34.1 weeks vs 40.0 weeks </p> <p><a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a>: median PFS 4.3 months vs 2.6 months </p> <p><a href="./references#CD007927-bbs2-0005" title="LiuJF , Ray‐CoquardI , SelleD , PovedaAM , CibulaD , HirteH , et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum‐resistant or ‐refractory ovarian cancer. Journal of Clinical Oncology2016; Vol. 34, issue 36:4345‐53. ">Lui 2016</a>: median PFS 3.75 months vs 3.68 months </p> <p><a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>: median PFS 2.9 months and 2.6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.90<br/> (0.70 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>658<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>due to the way HRs are calculated, the assumed and corresponding risks were not estimated.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 to 4 anaemia<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.47 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>652<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/> (37 to 116) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 diarrhoea<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.87<br/> (0.59 to 13.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>652<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diarrhoea differential side effect dependent upon type of anti‐EGFR antibody</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/> (12 to 283) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 diarrhoea ‐ pertuzumab<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.37<br/> (1.89 to 21.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>432<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diarrhoea was a more consistent side effect with pertuzumab when separated from trials of other anti‐EGFR inhibitors </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000<br/> (26 to 299) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 diarrhoea ‐ seribantumab<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.38<br/> (0.07 to 2.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/> (3 to 84) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 nausea ± vomiting<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/> (0.56 to 2.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>503<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/> (23 to 118) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 fatigue<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/> (0.66 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>652<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (63 to 164) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Toxicity: grade 3 or 4 hypokalaemia<br/> Assessed with National Cancer Institute Common Toxicity Criteria version 3 (CTCv3.0) or Common Terminology Criteria for Adverse Events (CTCAE) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.01<br/> (0.80 to 5.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>522<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/> (21 to 132) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Quality of life (QoL) (Hilpert data 2016 ‐ see additional references for <a href="./references#CD007927-bbs2-0004" title="ColomboN , Gonzalez‐MartinA , OestergaardMZ , RauJ , CanzlerU , FabbroM , et al. Biomarker results from PENELOPE, a randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC) with low tumour HER3 mRNA expression. International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:415‐7. HilpertF , GreimelE , OttevangerP , RauJ , LorussoD , KroepJ , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015, Nice, France:465‐6. HilpertF , Gropp‐MeierM , SchmalfeldtB , RauJ , MeierW , HasenburgA , et al. Patient‐reported outcome (PRO) results from the AGO‐OVAR 2.20/ENGOT‐ov14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). Oncology Research and Treatment2018; Vol. 39:138. Hoffmann‐LaRoche . A two‐part, randomized phase III, double‐blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum‐resistant epithelial ovarian cancer and low HER3 mRNA expression. Clinicaltrials.gov2012. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Double‐blind, placebo‐controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 MRNA‐expressing platinum‐resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology2016; Vol. 34, issue 21:2516‐25. KurzederC , BoverI , MarmeF , RauJ , PautierP , ColomboN , et al. Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum resistant ovarian cancer (PROC): AGOOVAR 2.20/ENGOTov14/ PENELOPE double‐blind, placebo‐controlled, randomized phase III trial. Journal of Clinical Oncology2015;15:5504. KurzederC , CampoJM , PautierP . PENELOPE/AGO‐OVAR 2.20: a double‐blind placebo (PLA)‐controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum‐resistant ovarian cancer. Journal of Clinical Oncology: ASCO Annual Meeting Proceedings2014;32:abstr TPS5613. LorussoD , Gonzalez‐MartinA , LuckHJ , RauJ , SelleF , ColomboN , et al. Final overall survival results from the double‐blind placebo‐controlled randomised phase III PENELOPE trial evaluating pertuzumab in platinum‐resistant ovarian cancer with low tumour HER3 MRNA expression. International Journal of Gynecological Cancer. Conference: 16th biennial meeting of the international gynecologic cancer society. Portugal. Conference start: 20161028. Conference end: 20161031 2017; Vol. 26:11‐2. MahnerS , LueckHJ , GrischkeEM , RauJ , Gropp‐MeierM , SchmalfeldtB , et al. Chemotherapy (CT) ± pertuzumab (P) for platinum‐resistant ovarian cancer (PROC): AGO‐OVAR 2.20/engot‐ov14/PENELOPE double‐blind placebo‐controlled randomized phase 3 trial. Oncology Research and Treatment2018; Vol. 39:S97. PautierP , PardoB , HilpertF , RauJ , GadducciA , SavareseA , et al. Subgroup analysis by chemotherapy cohort in the ago‐ovar 2.20/ENGOT‐OV14/PENELOPE double‐blind placebo‐controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum‐resistant ovarian cancer (PROC). International Journal of Gynecological Cancer2015; Vol. 25:24‐6. ">Kurzeder 2016</a> study): abdominal/gastrointestinal QoL (QLQ‐OV28) score 3.9 (95% CI ‐3.3 to 11.2); diarrhoeal symptoms QoL score worse on pertuzumab; score difference 21.2 (95% CI 10.1 to 32.3; P = 0.0003). <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a> (reported only in conference abstract form ‐ see Lalla 2008 in subsidiary references for <a href="./references#CD007927-bbs2-0006" title="GlennD , UelandF , BicherA , DizonD , GoldM , MakhijaS , et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum‐resistant ovarian cancer (OC): preliminary safety data [abstract]. Journal of Clinical Oncology; 2006 ASCO Annual Meeting Proceedings Part I,2006;24(Suppl):13001. LallaD , PatonV , LinCY , DizonDS . Affecting quality of life in ovarian cancer: encouraging results from a randomized phase II trial of gemcitabine ± pertuzumab in women with platinum‐resistant disease [Abstract]. Journal of Clinical Oncology2008;26(Suppl):Abstract 5550. MakhijaS , AmlerLC , GlennD , UelandFE , GoldMA , DizonDS , et al. Clinical activity of gemcitabine plus pertuzumab in platinum‐resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology2010;28(7):1215‐23. MakhijaS , GlennD , UelandF , GoldM , DizonD , PatonV , et al. Results from a phase II randomized, placebo‐controlled, double‐blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum‐resistant ovarian, fallopian tube or primary peritoneal cancer. Journal of Clinical Oncology2007;25(Suppl):Abstract 5507. ">Makhija 2010</a>): "The median time to symptom deterioration was 1.7 months in the gemcitabine+placebo arm vs. 3.8 months in the gemcitabine+pertuzumab arm (HR = 0.62, 95% CI: 0.36‐1.05). Symptom improvement (≥ 3 point increase in FOSI) occurred in 28 women (43%) given gemcitabine+pertuzumab, compared to 18 (28%) in those receiving gemcitabine+placebo". </p> <p>ClinicalTrials.gov identifier: NCT00096993</p> <p>This outcome was included in the original version of this review; no new results have been identified. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life was not reported consistently; narrative description of data is provided in review text, as data could not be added to meta‐analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; CTCAE: Common Terminology Criteria for Adverse Events; EGFR: epidermal growth factor receptor; HR: hazard ratio; OS: overall survival; PFS: progression‐free survival; QLQ‐OV28: European Organization for Research and Treatment of Cancer module for ovarian cancer; QoL: quality of life; RCT: randomised controlled trial; RR: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><a href="./references#CD007927-bbs2-0069" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐4. ">GRADE Working Group</a> grades of evidence<br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Outcome unlikely to be affected by lack of blinding. Downgraded by one level due to imprecision (wide confidence intervals that cross zero).<br/> <sup>b</sup>Downgraded by two levels due to lack of blinding in studies or unclear method of randomisation in studies and imprecision.<br/> <sup>c</sup>Downgraded by three levels for inconsistency between studies of different anti‐EGFR antibodies; imprecision; and lack of blinding or unclear method of randomisation in studies.<br/> <sup>d</sup>Downgraded by three levels due to imprecision (wide confidence intervals that cross zero and too few events for adequate power); lack of blinding or unclear method of randomisation in studies; and inconsistency (one study).<br/> <sup>e</sup>Downgraded by 3+ levels due to risk of bias (lack of blinding); inability to gauge inconsistency (only one study); minimal data presented and inability to assess adequately but wide confidence intervals; selective reporting bias as data collected but not presented in final publication; and risk of indirectness as symptom may be due to progression of disease rather than to treatment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/full#CD007927-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007927-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007927-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Toxicity: grade 3 or 4 neutropaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Toxicity: grade 3 or 4 febrile neutropaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Toxicity: grade 3 or 4 leucopaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Toxicity: grade 3 or 4 leucocytosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Toxicity: grade 3 or 4 thrombocytopaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Toxicity: grade 3 or 4 anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Toxicity: grade 3 or 4 nausea ± vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Toxicity: grade 3 or 4 constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Toxicity: grade 3 or 4 rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Toxicity: grade 3 or 4 allergic reaction/drug hypersensitivity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Toxicity: grade 3 or 4 skin toxicity (other) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Toxicity: grade 3 or 4 fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Toxicity: cardiac toxicity (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Toxicity: grade 3 or 4 hypokalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Toxicity: grade 3 or 4 hypocalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Toxicity: grade 3 or 4 hypomagnesaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Toxicity: grade 3 or 4 anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Toxicity: grade 3 or 4 neuropathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Toxicity: grade 3 or 4 oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Toxicity: treatment‐related secondary malignancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007927-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.74, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Platinum‐sensitive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.63, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Platinum‐resistant or refractory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.70, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.70, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Platinum‐sensitive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.81, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Platinum‐resistant or refractory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.63, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Toxicity: grade 3 or 4 neutropaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.64, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Pertuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.66, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Seribantumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.26, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Toxicity: grade 3 or 4 febrile neutropaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.10, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Toxicity: grade 3 or 4 leucopaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.28, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Toxicity: grade 3 or 4 thrombocytopaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.42, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Toxicity: grade 3 or 4 anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.47, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Pertuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.33, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Seribantumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.44, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Toxicity: grade 3 or 4 diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.59, 13.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Pertuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.37 [1.89, 21.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Seribantumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.07, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Toxicity: grade 3 or 4 nausea ± vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.56, 2.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Pertuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.54, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Seribantumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.23, 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Toxicity: grade 3 or 4 dyspepsia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Toxicity: grade 3 or 4 abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.49, 3.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Pertuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.14, 6.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Seribantumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.46, 4.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Toxicity: grade 3 or 4 rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Toxicity: grade 3 or 4 allergic reaction/drug hypersensitivity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Toxicity: grade 3 or 4 skin toxicity (other) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Toxicity: grade 3 or 4 fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.66, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Pertuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.57, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Seribantumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.52, 4.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Toxicity: cardiac toxicity (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.54, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Pertuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.54, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Toxicity: grade 3 or 4 hypokalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.80, 5.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Pertuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.47, 4.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Seribantumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.14 [0.71, 13.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Toxicity: grade 3 or 4 back pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007927.pub4/references#CD007927-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007927.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007927-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007927-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD007927-note-0002">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD007927-note-0004">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007927-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD007927-note-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007927-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007927\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007927\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007927\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007927\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007927\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007927.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007927.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007927.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007927.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007927.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726397015"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007927.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726397019"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007927.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e92a1290c9368',t:'MTc0MDcyNjM5Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 